

HEALTH ANNUAL STATEMENT

FOR THE YEAR ENDED DECEMBER 31, 2017 OF THE CONDITION AND AFFAIRS OF THE

Humana Medical Plan of Michigan, Inc.

NAIC C	Group Code 0119	0119 NAIC Company Cod	le <u>14224</u> Employer's I	D Number <u>27-3991410</u>
Organized under the Laws of	(Current) MIc	(Prior) higan ,	State of Domicile or Port of E	ntry MI
Country of Domicile		United States	of America	
Licensed as business type:		Health Maintenand	ce Organization	
Is HMO Federally Qualified?	es[]No[X]			
Incorporated/Organized	11/16/2010		Commenced Business	02/29/2012
Statutory Home Office	250 Monroe NW	/, Ste. 400 ,		Grand Rapids , MI, US 49503
	(Street and N	lumber)	(City o	r Town, State, Country and Zip Code)
Main Administrative Office		500 W. M (Street and		
(City or 7	Louisville , KY, US 40202			502-580-1000
, ,	own, State, Country and Zip	•	,	Area Code) (Telephone Number)
Mail Address	P.O. Box 74003 (Street and Number or F			Louisville , KY, US 40201-7436 r Town, State, Country and Zip Code)
Primary Location of Books and	Records	500 W. N	Main St.	
	Louisville , KY, US 40202	(Street and	Number)	502-580-1000
(City or	own, State, Country and Zip	Code)	(/	Area Code) (Telephone Number)
Internet Website Address		www.huma	ana.com	
Statutory Statement Contact	Ad	am Moss	,	502-580-3026
D	OIINQUIRIES@humana.com	(Name)		(Area Code) (Telephone Number) 502-580-2099
	(E-mail Address)			(FAX Number)
President & CEO	Bruce Dale	OFFIC Broussard	Sr. VP and CFO	Brian Andrew Kane
VP & Corporate Secretary			VP & Chief Actuary	
Alan James Bailey John Gregory Catron, VP &	Chief Compliance Officer	Elizabeth Diane Bierbowe Charles Wilbur Dow Jr., Reg Lakes	er, Pres, Group Segment g. PresSr. Products/Great Reg.	Renee Jacqueline Buckingham #, VP & Div. Leader - Northern Division Brian Phillip LeClaire, Ph.D., Sr. VP & Chief Information Officer
Susan Lynn Mateja #	, Appointed Actuary	Steven Edward McCulley, S George Renaudin II, Seg. VI	SVP, Medicare Operations P, Retail East and Provider	William Mark Preston, VP-Investment Management
Richard Donald Remme	rs, VP, Group Segment	Experi	ience	Donald Hank Robinson, Vice President - Tax Cynthia Hillebrand Zipperle, VP & Chief Accounting
Timothy Alan Wheatley, P	resident, Retail Segment	Ralph Martin Wilso	on, Vice President	Officer
Bruce Dale	Broussard	DIRECTORS OF Robert Michael Boch		Brian Andrew Kane #
			,	
State of County of	Kentucky Jefferson	SS:		
The officers of this reporting en all of the herein described ass statement, together with related condition and affairs of the said in accordance with the NAIC A rules or regulations require di respectively. Furthermore, the	tity being duly sworn, each de ets were the absolute proper exhibits, schedules and expl reporting entity as of the rep nnual Statement Instructions fferences in reporting not re scope of this attestation by t	ly of the said reporting entity, anations therein contained, an orting period stated above, and and Accounting Practices and elated to accounting practices he described officers also inclinations.	free and clear from any lien- nexed or referred to, is a full id d of its income and deductions d Procedures manual except is and procedures, according udes the related corresponding	coording entity, and that on the reporting period stated above so or claims thereon, except as herein stated, and that this and true statement of all the assets and liabilities and of the statement for the period ended, and have been completed to the extent that: (1) state law may differ; or, (2) that state to the best of their information, knowledge and beliefing electronic filing with the NAIC, when required, that is any be requested by various regulators in lieu of or in addition
Bruce Dale Brou President & C		Joseph Christop VP & Corporat		Alan James Bailey VP & Treasurer
Subscribed and sworn to before 23rd day of Michele Sizemore		iary, 2018	a. Is this an original filin b. If no, 1. State the amendm 2. Date filed	nent number
Notary Public January 3, 2019				

ASSETS

	-		Current Year		Prior Year
		1	2	3 Net Admitted Assets	4 Net Admitted
		Assets	Nonadmitted Assets	(Cols. 1 - 2)	Assets
1.	Bonds (Schedule D)	21,056,590	0	21,056,590	25,468,651
2.	Stocks (Schedule D):				
	2.1 Preferred stocks		0	0	0
3.	2.2 Common stocks	0			
٥.	3.1 First liens	0	0	0	0
	3.2 Other than first liens		0	0	0
4.	Real estate (Schedule A):				
	4.1 Properties occupied by the company (less \$				
	encumbrances)	0	0	0	0
	4.2 Properties held for the production of income (less				
	\$0 encumbrances)	0	0	0	0
	4.3 Properties held for sale (less \$0				
	encumbrances)	0	0	0	0
5.	Cash (\$(660,403), Schedule E - Part 1), cash equivalents				
	(\$12,536,085 , Schedule E - Part 2) and short-term				
	investments (\$274,891 , Schedule DA)				
	Contract loans, (including \$		0	0	0
7.	Derivatives (Schedule DB)		0	0	0
8. 9.	Other invested assets (Schedule BA)		0	0	0
10.	Securities lending reinvested collateral assets (Schedule DL)			0	0
11.	Aggregate write-ins for invested assets				
12.	Subtotals, cash and invested assets (Lines 1 to 11)				
13.	Title plants less \$0 charged off (for Title insurers	, ,		, ,	, ,
	only)	0	0	0	0
14.	Investment income due and accrued	235,966	0	235,966	217,873
15.	Premiums and considerations:				
	15.1 Uncollected premiums and agents' balances in the course of collection	620,196	179,245	440,951	747,288
	15.2 Deferred premiums and agents' balances and installments booked but				
	deferred and not yet due (including \$0				
	earned but unbilled premiums)	0	0	0	0
	15.3 Accrued retrospective premiums (\$	064 604	0	964 634	714 677
16.	Contracts subject to redetermination (\$	004,024	0	864,624	714,677
10.	16.1 Amounts recoverable from reinsurers	534 613	0	534 613	2 792 615
	16.2 Funds held by or deposited with reinsured companies				0
	16.3 Other amounts receivable under reinsurance contracts				0
17.	Amounts receivable relating to uninsured plans				95,480
18.1	Current federal and foreign income tax recoverable and interest thereon	0	0	0	3,703,567
	Net deferred tax asset			0	1,428,853
19.	Guaranty funds receivable or on deposit			0	0
20.	Electronic data processing equipment and software	0	0	0	0
21.	Furniture and equipment, including health care delivery assets				
	(\$				
	Net adjustment in assets and liabilities due to foreign exchange rates				0
23.	Receivables from parent, subsidiaries and affiliates			3, 153,650 1,331,337	
24. 25.	Health care (\$1,072,221) and other amounts receivable Aggregate write-ins for other than invested assets				
	Total assets excluding Separate Accounts Segregated Accounts and				
20.	Protected Cell Accounts (Lines 12 to 25)	49,721,093	9,891,461	39,829,632	70,013,161
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts	0	0		0
28.	Accounts Total (Lines 26 and 27)	49,721,093			70,013,161
	DETAILS OF WRITE-INS	49,721,090	3,031,401	09,029,002	70,013,101
1101.	DETAILS OF WHITE-ING				
1101.					
1102.					
1198.	Summary of remaining write-ins for Line 11 from overflow page			0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0		0	0
	Provider Contracts	7, 194, 494	7, 194, 494	0	0
	Prepaid Commissions		233,607	0	0
	Deposits		2,568	0	0
2598.	Summary of remaining write-ins for Line 25 from overflow page		0	0	0
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	7,430,669	7,430,669	0	0

LIABILITIES, CAPITAL AND SURPLUS

2. Accrue 3. Unpaid 4. Aggreg \$ Health 5. Aggreg 6. Propert 7. Aggreg 8. Premiu 9. Genera 10.1 Current (includ 10.2 Net def 11. Ceded 12. Amoun 13. Remitta 14. Borrow interes \$ 15. Amoun 16. Derivat 17. Payable 19. Funds I author reinsu 20. Reinsur compa 21. Net adj 22. Liability 23. Aggreg 24. Total lia 25. Aggreg 26. Commo 27. Preferm 28. Gross p 29. Surplus 30. Aggreg 31. Unassi 32. Less tro 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII					D : \/
2. Accrue 3. Unpaid 4. Aggreg \$ Health 5. Aggreg 6. Propert 7. Aggreg 8. Premiu 9. Genera 10.1 Current (includ 10.2 Net def 11. Ceded 12. Amoun 13. Remitta 14. Borrow interes \$ 15. Amoun 16. Derivat 17. Payable 18. Payable 19. Funds I author reinsu 20. Reinsur compa 21. Net adj 22. Liability 23. Aggreg 24. Total lia 25. Aggreg 26. Commo 27. Preferm 28. Gross p 29. Surplus 30. Aggreg 31. Unassie 32. Less tro 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII	<u> </u>	1	Current Year 2	3	Prior Year 4
2. Accrue 3. Unpaid 4. Aggreg \$ Health 5. Aggreg 6. Propert 7. Aggreg 8. Premiu 9. Genera 10.1 Current (includ 10.2 Net def 11. Ceded 12. Amoun 13. Remitta 14. Borrow interes \$ 15. Amoun 16. Derivat 17. Payable 18. Payable 19. Funds I author reinsu 20. Reinsur compa 21. Net adj 22. Liability 23. Aggreg 24. Total lia 25. Aggreg 26. Commo 27. Preferm 28. Gross p 29. Surplus 30. Aggreg 31. Unassie 32. Less tro 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII		1	2	3	4
2. Accrue 3. Unpaid 4. Aggreg \$ Health 5. Aggreg 6. Propert 7. Aggreg 8. Premiu 9. Genera 10.1 Current (includ 11. Ceded 12. Amoun 13. Remitta 14. Borrow interes \$ 15. Amoun 16. Derivat 17. Payable 18. Payable 19. Funds I author reinsu 20. Reinsur compa 21. Net adj 22. Liability 23. Aggreg 24. Total lia 25. Aggreg 26. Commo 27. Preferm 28. Gross I 29. Surplus 30. Aggreg 31. Unassi 32. Less tro 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII		Covered	Uncovered	Total	Total
3. Unpaid 4. Aggreg \$ Health 5. Aggreg 6. Propert 7. Aggreg 8. Premiu 9. Genera 10.1 Current (includ 10.2 Net def 11. Ceded 12. Amoun 13. Remitta 14. Borrow interes \$ 15. Amoun 16. Derivat 17. Payable 19. Funds I author reinsu 20. Reinsu compa 21. Net adj 22. Liability 23. Aggreg currer 24. Total lia 25. Aggreg 26. Comm 27. Prefern 28. Gross I 29. Surplus 30. Aggreg 31. Unassi 32. Less tra 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII	Claims unpaid (less \$0 reinsurance ceded)	6,948,956	651,222	7,600,178	12,274,593
4. Aggreg \$ Health 5. Aggreg 6. Propert 7. Aggreg 8. Premiu 9. Genera 10.1 Current (includ 10.2 Net def 11. Ceded 12. Amoun 13. Remitta 14. Borrow interes \$ 15. Amoun 16. Derivat 17. Payable 19. Funds I author reinsu 20. Reinsul compa 21. Net adj 22. Liability 23. Aggreg currer 24. Total lia 25. Aggreg 26. Comma 27. Preferra 28. Gross I 29. Surplus 30. Aggreg 31. Unassi 32. Less tra 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII	Accrued medical incentive pool and bonus amounts	471,545	0	471,545	0
4. Aggreg \$ Health 5. Aggreg 6. Propert 7. Aggreg 8. Premiu 9. Genera 10.1 Current (includ 10.2 Net def 11. Ceded 12. Amoun 13. Remitta 14. Borrow interes \$ 15. Amoun 16. Derivat 17. Payable 19. Funds I author reinsu 20. Reinsul compa 21. Net adj 22. Liability 23. Aggreg currer 24. Total lia 25. Aggreg 26. Comma 27. Preferra 28. Gross I 29. Surplus 30. Aggreg 31. Unassi 32. Less tra 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII	Inpaid claims adjustment expenses	59,608	0	59,608	92,949
\$ Health 5. Aggreg 6. Propert 7. Aggreg 8. Premiu 9. Genera 10.1 Current (includ 10.2 Net def 11. Ceded 12. Amoun 13. Remitta 14. Borrow interes \$ 15. Amoun 16. Derivat 17. Payable 19. Funds h author reinsu 20. Reinsul compa 21. Net adj 22. Liability 23. Aggreg 24. Total lia 25. Aggreg 26. Comma 27. Preferra 28. Gross p 29. Surplus 30. Aggreg 31. Unassie 30. Aggreg 31. Unassie 32. Less tra 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII	aggregate health policy reserves, including the liability of				
Health 5. Aggreg 6. Propert 7. Aggreg 8. Premiu 9. Genera 10.1 Current (includ 10.2 Net def 11. Ceded 12. Amoun 13. Remitta 14. Borrow interes \$ 15. Amoun 16. Derivat 17. Payable 19. Funds I author reinsu 20. Reinsur compa 21. Net adj 22. Liability 23. Aggreg currer 24. Total lia 25. Aggreg 26. Commo 27. Preferre 28. Gross I 29. Surplus 30. Aggreg 31. Unassie 32. Less tre 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII	\$0 for medical loss ratio rebate per the Public				
5. Aggreg 6. Propert 7. Aggreg 8. Premiu 9. Genera 10.1 Current (includ 10.2 Net def 11. Ceded 12. Amoun 13. Remitta 14. Borrow interes \$ 15. Amoun 16. Derivat 17. Payable 19. Funds I author reinsu 20. Reinsur compa 21. Net adj 22. Liability 23. Aggreg currer 24. Total lia 25. Aggreg 26. Commo 27. Preferm 28. Gross p 29. Surplus 30. Aggreg 31. Unassie 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII	Health Service Act	3 094 565	0	3 094 565	15 801 404
6. Propert 7. Aggreg 8. Premiu 9. Genera 10.1 Current (includ 10.2 Net def 11. Ceded 12. Amoun 13. Remitta 14. Borrow interes \$ 15. Amoun 16. Derivat 17. Payable 18. Payable 19. Funds I author reinsu 20. Reinsur compa 21. Net adj 22. Liability 23. Aggreg currer 24. Total lia 25. Aggreg 26. Commo 27. Preferm 28. Gross p 29. Surplus 30. Aggreg 31. Unassi 32. Less tro 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII	Aggregate life policy reserves.				0
7. Aggreg 8. Premiu 9. Genera 10.1 Current (includ 10.2 Net def 11. Ceded 12. Amoun 13. Remitta 14. Borrow interes \$ 15. Amoun 16. Derivat 17. Payable 19. Funds I author reinsu 20. Reinsu compa 21. Net adj 22. Liability 23. Aggreg currer 24. Total lia 25. Aggreg 26. Comma 27. Preferm 28. Gross I 29. Surplus 30. Aggreg 31. Unassi 32. Less tra 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII					_
8. Premiu 9. Genera 10.1 Current (includ 10.2 Net def 11. Ceded 12. Amoun 13. Remitta 14. Borrow interes \$ 15. Amoun 16. Derivat 17. Payable 19. Funds I author reinsu 20. Reinsul compa 21. Net adj 22. Liability 23. Aggreg currer 24. Total lia 25. Aggreg 26. Comma 27. Preferra 28. Gross I 29. Surplus 30. Aggreg 31. Unassi 32. Less tra 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII	Property/casualty unearned premium reserves				0
9. Genera 10.1 Current (includ) 10.2 Net def 11. Ceded 12. Amoun 13. Remitta 14. Borrow interes \$ 15. Amoun 16. Derivat 17. Payable 19. Funds I author reinsu 20. Reinsur compa 21. Net adj 22. Liability 23. Aggreg currer 24. Total lia 25. Aggreg 26. Comma 27. Preferra 28. Gross I 29. Surplus 30. Aggreg 31. Unassi 32. Less tra 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII	aggregate health claim reserves		0		0
10.1 Current (included) 10.2 Net def 11. Ceded 12. Amoun 13. Remitta 14. Borrown interes \$ 15. Amoun 16. Derivat 17. Payable 19. Funds h author reinsu 20. Reinsur compa 21. Net adj 22. Liability 23. Aggreg currer 24. Total lia 25. Aggreg 26. Commo 27. Preferre 28. Gross p 29. Surplus 30. Aggreg 31. Unassie 32. Less tre 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII	Premiums received in advance			1,346,421	1,723,926
(included) 10.2 Net def 11. Ceded 12. Amoun 13. Remitta 14. Borrow interes \$ 15. Amoun 16. Derivat 17. Payabla 18. Payabla 19. Funds I author reinsu 20. Reinsul compa 21. Net adj 22. Liability 23. Aggreg currer 24. Total lia 25. Aggreg 26. Commo 27. Preferra 28. Gross I 29. Surplus 30. Aggreg 31. Unassi 32. Less tra 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII	General expenses due or accrued	143,699	0	143,699	709,690
10.2 Net def 11. Ceded 12. Amoun 13. Remitta 14. Borrow interes \$ 15. Amoun 16. Derivat 17. Payable 18. Payable 19. Funds I author reinsu 20. Reinsur compa 21. Net adj 22. Liability 23. Aggreg currer 24. Total lia 25. Aggreg 26. Commo 27. Preferr 28. Gross p 29. Surplus 30. Aggreg 31. Unassi 32. Less tro 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII	Current federal and foreign income tax payable and interest thereon				
10.2 Net def 11. Ceded 12. Amoun 13. Remitta 14. Borrow interes \$ 15. Amoun 16. Derivat 17. Payable 18. Payable 19. Funds I author reinsu 20. Reinsur compa 21. Net adj 22. Liability 23. Aggreg currer 24. Total lia 25. Aggreg 26. Commo 27. Preferr 28. Gross p 29. Surplus 30. Aggreg 31. Unassi 32. Less tro 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII	(including \$(71,206) on realized capital gains (losses))	740,603	0	740,603	0
11. Ceded 12. Amoun 13. Remitta 14. Borrow interes \$ 15. Amoun 16. Derivat 17. Payable 18. Payable 19. Funds I author reinsu 20. Reinsu compa 21. Net adj 22. Liability 23. Aggreg currer 24. Total lia 25. Aggreg 26. Comma 27. Preferm 28. Gross I 29. Surplus 30. Aggreg 31. Unassi 32. Less tra 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII	let deferred tax liability				0
12. Amoun 13. Remitta 14. Borrow interes \$ 15. Amoun 16. Derivat 17. Payable 19. Funds I author reinsu 20. Reinsu compa 21. Net adj 22. Liability 23. Aggreg currer 24. Total lia 25. Aggreg 26. Comm 27. Preferr 28. Gross I 29. Surplus 30. Aggreg 31. Unassi 32. Less tra 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII	Ceded reinsurance premiums payable				647.298
13. Remitta 14. Borrow interes \$ 15. Amoun 16. Derivat 17. Payable 18. Payable 19. Funds I author reinsu 20. Reinsur compa 21. Net adj 22. Liability 23. Aggreg currer 24. Total lia 25. Aggreg 26. Commo 27. Preferre 28. Gross I 29. Surplus 30. Aggreg 31. Unassi 32. Less tre 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII					, ,
14. Borrow interes \$	Amounts withheld or retained for the account of others		0		0
interes \$ 15. Amoun 16. Derivat 17. Payable 18. Payable 19. Funds I author reinsu 20. Reinsur compa 21. Net adj 22. Liability 23. Aggreg currer 24. Total lia 25. Aggreg 26. Commo 27. Preferre 28. Gross p 29. Surplus 30. Aggreg 31. Unassie 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII	Remittances and items not allocated	693,745	0	693,745	54 , 191
\$ 15. Amoun 16. Derivat 17. Payable 18. Payable 19. Funds I author reinsu 20. Reinsul compa 21. Net adj 22. Liability 23. Aggreg currer 24. Total lia 25. Aggreg 26. Comma 27. Preferr 28. Gross p 29. Surplus 30. Aggreg 31. Unassi 32. Less tra 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII	Sorrowed money (including \$0 current) and				
15. Amoun 16. Derivat 17. Payable 18. Payable 19. Funds I author reinsu 20. Reinsu compa 21. Net adj 22. Liability 23. Aggreg currer 24. Total lia 25. Aggreg 26. Comma 27. Preferm 28. Gross I 29. Surplus 30. Aggreg 31. Unassi 32. Less tra 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia	interest thereon \$0 (including				
15. Amoun 16. Derivat 17. Payable 18. Payable 19. Funds I author reinsu 20. Reinsu compa 21. Net adj 22. Liability 23. Aggreg currer 24. Total lia 25. Aggreg 26. Comma 27. Preferm 28. Gross I 29. Surplus 30. Aggreg 31. Unassi 32. Less tra 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia	\$0 current)	0	0	0	0
16. Derivat 17. Payable 18. Payable 19. Funds I author reinsu 20. Reinsu compa 21. Net adj 22. Liability 23. Aggreg currer 24. Total lia 25. Aggreg 26. Comma 27. Preferra 28. Gross I 29. Surplus 30. Aggreg 31. Unassi 32. Less tra 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII	mounts due to parent, subsidiaries and affiliates			0	3,448,783
17. Payable 18. Payable 19. Funds I author reinsu 20. Reinsur compa 21. Net adj 22. Liability 23. Aggreg currer 24. Total lia 25. Aggreg 26. Commo 27. Preferre 28. Gross I 29. Surplus 30. Aggreg 31. Unassi 32. Less tre 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII	Perivatives.			.0	
18. Payable 19. Funds I author reinsu 20. Reinsur compa 21. Net adj 22. Liability 23. Aggreg currer 24. Total lia 25. Aggreg 26. Commo 27. Preferre 28. Gross p 29. Surplus 30. Aggreg 31. Unassie 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII					
19. Funds I author reinsu 20. Reinsu compa 21. Net adj 22. Liability 23. Aggreg currer 24. Total lia 25. Aggreg 26. Commo 27. Preferr 28. Gross p 29. Surplus 30. Aggreg 31. Unassi 32. Less tr 32.1 \$ 33. Total ca 34. Total lia DETAII	Payable for securities			0	
author reinsu 20. Reinsur compa 21. Net adj 22. Liability 23. Aggrega currer 24. Total lia 25. Aggreg 26. Commo 27. Preferro 28. Gross p 29. Surplus 30. Aggreg 31. Unassig 32. Less tro 32.1	Payable for securities lending	0	0	0	0
reinsu 20. Reinsur compa 21. Net adj 22. Liability 23. Aggreg currer 24. Total lia 25. Aggreg 26. Commo 27. Preferm 28. Gross p 29. Surplus 30. Aggreg 31. Unassin 32. Less tro 32.1 \$ \$ 32.2 \$ 33. Total ca 34. Total lia DETAII	unds held under reinsurance treaties (with \$0				
20. Reinsul compa 21. Net adj 22. Liability 23. Aggregi currer 24. Total lia 25. Aggreg 26. Comma 27. Preferra 28. Gross p 29. Surplus 30. Aggreg 31. Unassig 32. Less tra 32.1 \$ 32.2 \$ 31. Total ca 34. Total lia	authorized reinsurers, \$0 unauthorized				
20. Reinsul compa 21. Net adj 22. Liability 23. Aggregi currer 24. Total lia 25. Aggreg 26. Comma 27. Preferra 28. Gross p 29. Surplus 30. Aggreg 31. Unassig 32. Less tra 32.1 \$ 32.2 \$ 31. Total ca 34. Total lia	reinsurers and \$0 certified reinsurers)	0	0	0	0
compa 21. Net adj 22. Liability 23. Aggregi currer 24. Total lia 25. Aggreg 26. Comma 27. Preferra 28. Gross p 29. Surplus 30. Aggreg 31. Unassi 32. Less tra 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII	Reinsurance in unauthorized and certified (\$0)				
21. Net adj 22. Liability 23. Aggreg currer 24. Total lia 25. Aggreg 26. Commo 27. Preferro 28. Gross p 29. Surplus 30. Aggreg 31. Unassig 32. Less tro 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia	companies	0	0	0	0
22. Liability 23. Aggregature 24. Total lia 25. Aggregature 26. Common 27. Preferro 28. Gross p 29. Surplus 30. Aggregature 31. Unassign 32.1					
23. Aggreg:	let adjustments in assets and liabilities due to foreign exchange rates				
24. Total lia 25. Aggreg 26. Commo 27. Preferm 28. Gross p 29. Surplus 30. Aggreg 31. Unassin 32. Less tra 32.1 \$ 33. Total ca 34. Total lia	iability for amounts held under uninsured plans	1,307,075	0	1,307,075	4, 116, 550
24. Total lia 25. Aggreg 26. Commo 27. Preferro 28. Gross p 29. Surplus 30. Aggreg 31. Unassig 32. Less tro 32.1 \$ 32.2 \$ 31. Total ca 34. Total lia	ggregate write-ins for other liabilities (including \$21,653				
25. Aggreg 26. Commo 27. Preferro 28. Gross p 29. Surplus 30. Aggreg 31. Unassig 32. Less tro 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia	current)				
25. Aggreg 26. Commo 27. Preferro 28. Gross p 29. Surplus 30. Aggreg 31. Unassig 32. Less tro 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia	otal liabilities (Lines 1 to 23)	14,845,427	651,222	15,496,649	38,869,384
26. Commo 27. Preferro 28. Gross p 29. Surplus 30. Aggreg 31. Unassig 32. Less tre 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia	aggregate write-ins for special surplus funds				
27. Preferri 28. Gross p 29. Surplus 30. Aggreg 31. Unassig 32.1	Common capital stock				
28. Gross p 29. Surplus 30. Aggreg 31. Unassin 32. Less tra 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia	Preferred capital stock				0
29. Surplus 30. Aggreg 31. Unassig 32. Less tro 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia					44,999,000
30. Aggreg 31. Unassig 32. Less tre 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia	Gross paid in and contributed surplus				
31. Unassigned 32.1 Less tree 32.1	Surplus notes				
32. Less tre 32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAIL	Aggregate write-ins for other than special surplus funds	XXX	XXX	0	0
32.1 \$ 32.2 \$ 33. Total ca 34. Total lia DETAII	Jnassigned funds (surplus)	XXX	XXX	(21,886,452)	(13,856,223)
\$ 32.2 \$ 33. Total ca 34. Total lia	ess treasury stock, at cost:				
\$ 32.2 \$ 33. Total ca 34. Total lia	2.10 shares common (value included in Line 26				
32.2 \$ 33. Total ca 34. Total lia	\$0)	VVV	XXX	0	0
\$ 33. Total ca 34. Total lia	2.2				0
33. Total ca		NO.07	1007		•
34. Total lia	\$				
DETAII	otal capital and surplus (Lines 25 to 31 minus Line 32)	XXX	XXX	24,332,983	31,143,777
	otal liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	39,829,632	70,013,161
2201 10010:-	DETAILS OF WRITE-INS				
ı ∠ouı. U∏CIäl∏	nclaimed Property	39,210	0	39,210	0
					-
	Summary of remaining write-ins for Line 23 from overflow page				0
	otals (Lines 2301 thru 2303 plus 2398)(Line 23 above)	39,210	0	39,210	0
2501. Special	pecial Surplus - Projected HCRL Assessment for the Upcoming Year	XXX	XXX	1,219,435	0
	Summary of remaining write-ins for Line 25 from overflow page				0
	otals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	XXX	XXX	1,219,435	0
3003		xxx	XXX		
3099. Totals (Summary of remaining write-ins for Line 30 from overflow page	XXX	L		

STATEMENT OF REVENUE AND EXPENSES

	STATEMENT OF REVENUE AT	Current		Prior Year
		1	2	3
		Uncovered	Total	Total
1.	Member Months	XXX	136,216	403,310
2.	Net premium income (including \$ non-health premium income)	XXX	77,258,310	128,682,393
3.	Change in unearned premium reserves and reserve for rate credits	XXX	0	(13,537,824)
4.	Fee-for-service (net of \$0 medical expenses)			
	Risk revenue			
5.				
6.	Aggregate write-ins for other health care related revenues			
7.	Aggregate write-ins for other non-health revenues			
8.	Total revenues (Lines 2 to 7)	XXX	77,258,310	115,144,569
	Hospital and Medical:			
9.	Hospital/medical benefits	5 , 529 , 644	54,830,156	82,682,610
10.	Other professional services	0	1,483,146	1,661,809
11.	Outside referrals	0	0	0
12.	Emergency room and out-of-area	408,599	2,950,554	3,851,411
13.	Prescription drugs			
	Aggregate write-ins for other hospital and medical			0
14.				
15.	Incentive pool, withhold adjustments and bonus amounts			
16.	Subtotal (Lines 9 to 15)	5,938,243	67,439,423	100 , 555 , 165
	Less:			
17.	Net reinsurance recoveries	0	811,274	1,699,878
18.	Total hospital and medical (Lines 16 minus 17)	5,938,243	66,628,149	98,855,287
19.	Non-health claims (net)	0	0	0
20.	Claims adjustment expenses, including \$2,576,301 cost containment expenses	0	3,445,531	5,565,337
21.	General administrative expenses			
			, , , , , , , , , , , , , , , , ,	
22.	Increase in reserves for life and accident and health contracts (including \$0		0.075.000	
	increase in reserves for life only)			
23.	Total underwriting deductions (Lines 18 through 22)	5,938,243	80,080,136	126,659,240
24.	Net underwriting gain or (loss) (Lines 8 minus 23)	XXX	(2,821,826)	(11,514,671)
25.	Net investment income earned (Exhibit of Net Investment Income, Line 17)	0	720,481	422,837
26.	Net realized capital gains (losses) less capital gains tax of \$(83,186)	0	(154,488)	(63,430)
27.	Net investment gains (losses) (Lines 25 plus 26)			359,407
28.	Net gain or (loss) from agents' or premium balances charged off [(amount recovered		,	ŕ
	\$0) (amount charged off \$	0	0	0
29.	Aggregate write-ins for other income or expenses	0	5	0
30.	Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 plus 28 plus 29)	XXX	(2,255,828)	(11, 155, 264)
31.	Federal and foreign income taxes incurred	XXX	(210,441)	(3, 182, 835)
32.	Net income (loss) (Lines 30 minus 31)	XXX	(2,045,387)	(7,972,429)
	DETAILS OF WRITE-INS			
0601.		XXX		
0602.				
0603				
	Summary of remaining write-ins for Line 6 from overflow page		0	0
0698.			0	0
0699.	Totals (Lines 0601 thru 0603 plus 0698)(Line 6 above)	XXX	0	0
0701.		XXX		
0702.				
0703				
0798.	Summary of remaining write-ins for Line 7 from overflow page	XXX	0	0
0799.	Totals (Lines 0701 thru 0703 plus 0798)(Line 7 above)	XXX	0	0
1401.				
1402.				
1403.				
1498.	Summary of remaining write-ins for Line 14 from overflow page	0	0	0
1499.	Totals (Lines 1401 thru 1403 plus 1498)(Line 14 above)	0	0	0
2901.	Miscellaneous Income	0	5	0
2902.				
2903				
2998.	Summary of remaining write-ins for Line 29 from overflow page	0	0	0
	, ,	0	5	0
2999.	Totals (Lines 2901 thru 2903 plus 2998)(Line 29 above)	U	١	U

STATEMENT OF REVENUE AND EXPENSES (Continued)

1	STATEMENT OF REVENUE AND EXPENSES	Continued	2
		Current Year	Prior Year
	CAPITAL AND SURPLUS ACCOUNT		
33.	Capital and surplus prior reporting year.	31,143,777	21,019,513
34.	Net income or (loss) from Line 32		
35.	Change in valuation basis of aggregate policy and claim reserves	0	0
200	Change in net unrealized capital gains (losses) less capital gains tax of \$0		
36.			
37.	Change in net unrealized foreign exchange capital gain or (loss)		
38.	Change in net deferred income tax		
39.	Change in nonadmitted assets		
40	Change in unauthorized and certified reinsurance		
41.	Change in treasury stock		
42.	Change in surplus notes	0	0
43.	Cumulative effect of changes in accounting principles.	0	0
44.	Capital Changes:		
	44.1 Paid in	0	0
	44.2 Transferred from surplus (Stock Dividend)	0	0
	44.3 Transferred to surplus.	0	0
45.	Surplus adjustments:		
	45.1 Paid in	0	10,000,000
	45.2 Transferred to capital (Stock Dividend)	0	0
	45.3 Transferred from capital	0	0
46.	Dividends to stockholders	0	0
47.	Aggregate write-ins for gains or (losses) in surplus	(194,239)	1,625,000
48.	Net change in capital and surplus (Lines 34 to 47)		
49.	Capital and surplus end of reporting period (Line 33 plus 48)	24,332,983	31,143,777
_	DETAILS OF WRITE-INS		
4701.	2016 Risk Corridor impact on Premium Deficiency Reserve	0	1 625 000
4702.	Prior Period Impact of Claims Dispute		
4703.	Cumpour of remaining write ing feet ing 47 from gradient and		
4798.	Summary of remaining write-ins for Line 47 from overflow page		0
4799.	Totals (Lines 4701 thru 4703 plus 4798)(Line 47 above)	(194,239)	1,625,000

CASH FLOW

		1	2
	Oracle from Oracletians	Current Year	Prior Year
	Cash from Operations	61 017 674	107 504 050
1.	Premiums collected net of reinsurance		
2.	Net investment income	_	
3.	Miscellaneous income		128,092,266
4.	Total (Lines 1 through 3)		
5.	Benefit and loss related payments		93,892,551
6.	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts		0
7.	Commissions, expenses paid and aggregate write-ins for deductions		
8.	Dividends paid to policyholders		
9.	Federal and foreign income taxes paid (recovered) net of \$(66,470) tax on capital gains (losses)		1,527,242
10.	Total (Lines 5 through 9)		122,836,370
11.	Net cash from operations (Line 4 minus Line 10)	(16,126,757)	5,255,896
	Cash from Investments		
12.	Proceeds from investments sold, matured or repaid:		
	12.1 Bonds		
	12.2 Stocks		0
	12.3 Mortgage loans		0
	12.4 Real estate		
	12.5 Other invested assets		
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments		
	12.7 Miscellaneous proceeds		0
	12.8 Total investment proceeds (Lines 12.1 to 12.7)	14,333,299	12,795,118
13.	Cost of investments acquired (long-term only):		
	13.1 Bonds	10,561,045	35,614,438
	13.2 Stocks	0	0
	13.3 Mortgage loans	0	0
	13.4 Real estate	0	0
	13.5 Other invested assets	0	0
	13.6 Miscellaneous applications	0	0
	13.7 Total investments acquired (Lines 13.1 to 13.6)	10,561,045	35,614,438
14.	Net increase (decrease) in contract loans and premium notes	0	0
15.	Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)	3,772,254	(22,819,320)
	Cash from Financing and Miscellaneous Sources		
16.	Cash provided (applied):		
	16.1 Surplus notes, capital notes		
	16.2 Capital and paid in surplus, less treasury stock	0	10,000,000
	16.3 Borrowed funds		
	16.4 Net deposits on deposit-type contracts and other insurance liabilities	0	0
	16.5 Dividends to stockholders	0	0
	16.6 Other cash provided (applied)	(9, 104, 753)	437,140
17.	Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)	(9,104,753)	10,437,140
	DECONORMATION OF CARRY CARRY FAUTO AND SUCCESSION		
10	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS	(21 450 256)	/7 10E 004\\
18.	Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	(21,459,256)	(7,126,284)
19.	Cash, cash equivalents and short-term investments:	20, 600, 000	40 700 440
	19.1 Beginning of year		40,736,113
	19.2 End of year (Line 18 plus Line 19.1)	12,150,573	33,609,829

Note: Supplemental disclosures of cash flow information for non-cash transactions:		

ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

Net permission record Total Comprehensive Total Medicare Comprehensive Total Medicare Comprehensive Total Total Medicare Comprehensive Total Total Total Medicare Comprehensive Total				1AL 1313 U	1 OI LILF	TIONS D	I LINLS					
1. Not promium notions			1	2 Comprehensive	· ·	•		Federal Employees			9	10 Other
2. Charge in unantance parameter reserves and reserve for into credit in the credit of the control of the contr			Total	(Hospital & Medical)	Supplement	Only	Only	Benefits Plan	Medicare	Medicaid	Other Health	Non-Health
2. Charge in unantance parameter reserves and reserve for into credit in the credit of the control of the contr	1.	Net premium income	77,258,310	18,636,059	0	0	0	0	58,622,251	0	0	0
3. February 1. February		Change in unearned premium reserves and reserve for	0		0	0	0	0		0	0	0
Miscal expenses)	3	Fee-for-service (net of \$ 0										
4. Risk revenue	0.		0	0	0	0	0	0	0	0	0	XXX
5. Aggregate write-ins for other health care related revenues.	4	, ,	0	0	0	 0	0	0	0	0	0	
6. Aggingsate wine-instructions in 60. 77. Zero inventioned, Lines 1 invention	5.	Aggregate write-ins for other health care related	0	0	0	0	0	0	0	0	0	
7. Total recenture (Lines 10 16)	6.	Aggregate write-ins for other non-health care related	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
8. Hospitalmedical benefits	7		77 258 310					0		0		0
9. Other professional services					0	0	0	0	, , .	0		XXX
10. Outside referrals	_	·			0	0	0	0		0	0	
11. Emergency room and out-of-area 2.80,5% 57,76" 0 0 0 0 2,276,76" 3 0 XXX 12. Prescription drugs 6.80,0% 3.387,116 0 0 0 0 0 3,213,96 0 0 0 XXX 13. Aggregate write-ins for other hospital and medical 0 0 0 0 0 0 0 0 0	_				0	0	0	0		0		
12. Prescription drugs			2.950.554	673.767	0	0	0	0	2.276.787	0	0	
13. Aggregate write-ins for other hospital and medical 0					0	0	0	0		0	0	
14. Incentive pool, withhold adjustments and borus amounts				0	0	0	0	0		0		
15. Subtotal (Lines 8 to 14)				0	0	0	0	0	1 574 605	0	0	
16 Net reinsurance recoveries				14 820 407	0	0	0	0		0		
17. Total medical and hospital (Lines 15 minus 16)					0	0	0	0		0	0	
18. Non-health claims (net)					0	 0	0	0		0	0	
19. Claims adjustment expenses including S _ 2.75, 31 cost containment expenses 3,445,331 1,518,771 0 0 0 0 1,926,760 0 0 0 0 0 0 0 0 0			0		XXX	XXX	XXX	XXX		XXX		0
\$ \frac{2.578.30!}{2.578.30!} cost containment expenses	_	` '		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,							,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
20. General administrative expenses	10.		3 445 531	1 518 771	0	0	0	0	1 926 760	0	0	0
21. Increase in reserves for accident and health contracts	20	General administrative expenses			n	ر ۱	0	0		٥	0	0
22 Increase in reserves for life contracts	_			,	n	ر ۱	0	0		٥		XXX
23. Total underwriting deductions (Lines 17 to 22)					XXX					XXX		0
24. Total underwriting gain or (loss) (Line 7 minus Line 23)					n			0			0	0
DETAILS OF WRITE-INS					n	ر ۱	0	0	, ,	٥	0	0
Sociation Summary of remaining write-ins for Line 5 from overflow page Description Descripti		DETAILS OF WRITE-INS	(2,021,020)	30,707	v				(2,000,000)	U		
0.503							+	+	 			
Summary of remaining write-ins for Line 5 from overflow page							-	+	 			
Object	0503. 0598.							<u> </u>	<u></u>			
0601	0500			} <u>0</u> }	ا ۵		J	ļ	<u> </u>		الا	
0602		Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	0	VVV	0		·	*	· ·	•	· ·	XXX
0603.												
0698. Summary of remaining write-ins for Line 6 from overflow page 0 XXX									T			
page				XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
1301.		page	0									0
1302	0699.	Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
1303. ———————————————————————————————————												
1398. Summary of remaining write-ins for Line 13 from overflow page									 			
overflow page 0 0 0 0 0 0 0 0 0 0 XXX									ļ			XXX
1399. Totals (Lines 1301 thru 1303 plus 1398) (Line 13 above) 0 0 0 0 0 XXX	1398.		0	0	0	0	0	0	0	0	0	xxx
	1399.	Totals (Lines 1301 thru 1303 plus 1398) (Line 13 above)	0	0	0	0	0	0	0	0	0	XXX

UNDERWRITING AND INVESTMENT EXHIBIT

PART 1 - PREMIUMS

	1	2	3	4
Line of Business	Direct Business	Reinsurance Assumed	Reinsurance Ceded	Net Premium Income (Cols. 1 + 2 - 3)
Comprehensive (hospital and medical)	18,636,000	0	(59)	18,636,059
2. Medicare Supplement	0	0	0	0
3. Dental only	0	0	0	0
4. Vision only	0	0	0	0
5. Federal Employees Health Benefits Plan	0	0	0	0
6. Title XVIII - Medicare	58,625,747	0	3,496	58,622,251
7. Title XIX - Medicaid	0	0	0	0
8. Other health	0	0	0	0
9. Health subtotal (Lines 1 through 8)	77,261,747	0	3,437	77,258,310
10. Life	0	0	0	0
11. Property/casualty	0	0	0	0
12. Totals (Lines 9 to 11)	77,261,747	0	3,437	77,258,310

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2 - CLAIMS INCURRED DURING THE YEAR

				PART 2 - CLA	IMS INCURRED DUI	TING THE TEAN					
		1	2	3	4	5	6 Federal	7	8	9	10
		Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Other Health	Other Non-Health
1.	Payments during the year:										
	1.1 Direct	70,876,052	21,363,574	0	0	0	0	49,512,478	0	0	0
	1.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
	1.3 Reinsurance ceded	3,315,925	3,315,925	0	0	0	0	0	0	0	0
	1.4 Net	67,560,127	18,047,649	0	0	0	0	49,512,478	0 L	0	0
2.	Paid medical incentive pools and bonuses	1,103,060	0	0	0	0	0	1,103,060	0	0	0
	Claim liability December 31, current year from Part 2A:	, ,						, ,			
	3.1 Direct	7,600,178	1,924,825	0	0	0	0	5,675,353	0	0	0
	3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
	3.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
	3.4 Net	7,600,178	1,924,825	0	0	0	0	5,675,353	0	0	0
4.	Claim reserve December 31, current year from Part 2D:	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	1,021,020					0			
	4.1 Direct	0	0	0	0	0	0	0	0	0	0
	4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
	4.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
	4.4 Net	0	0	0	0	0	0	0	0	0	0
5.	Accrued medical incentive pools and bonuses, current year	471,545	0	0	0	0	0	471,545	0	0	0
6.	Net healthcare receivables (a)	90,170	(278, 144)	0	0	0	0	368,314	0	0	0
7.	Amounts recoverable from reinsurers December 31, current year	534,613	534,613	0	0	0	0	0	0	0	0
8.	Claim liability December 31, prior year from Part 2A: 8.1 Direct	12,521,242	8,746,136	0	0	0	0	3.775.106	0	0	0
	8.2 Reinsurance assumed		, ۵,740,130			٥	0	0,775,100			٥٠
	8.3 Reinsurance ceded	246,649	246,649								٥٥
							0	0.775.400			0
_	8.4 Net	12,274,593	8,499,487			0	0	3,775,106	U		0
9.	Claim reserve December 31, prior year from Part 2D:	0		0		•		0			•
	9.1 Direct	0				0	0				0
	9.2 Reinsurance assumed	0	0	0	0	0	0	0	0		0
	9.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
	9.4 Net	0	0	0	0	0	0	0	0	0	0
10.	Accrued medical incentive pools and bonuses, prior year	0	0	0	0	0	0	0	0	0	0
11.	Amounts recoverable from reinsurers December 31,	0 700 045	0.700.045			•					•
	prior year	2,792,615	2,792,615	0	0	0	0	0	0	0	0
12.	Incurred Benefits:										
	12.1 Direct	65,864,818	14,820,407	0	0	0	0	51,044,411	0	0	0
	12.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
	12.3 Reinsurance ceded	811,274	811,274	0	0	0	0	0	0	0	0
	12.4 Net	65,053,544	14,009,133	0	0	0	0	51,044,411	0	0	0
13.	Incurred medical incentive pools and bonuses	1,574,605	0	0	0	0	0	1,574,605	0	0	0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

			FART ZA - CLAIN	IS LIABILITY END	JE CUNNENT TEAR	<u>n</u>				
	1	2	3	4	5	6 Federal Employees	7 Title	8 Title	9	10
	Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Health Benefits Plan	XVIII Medicare	XIX Medicaid	Other Health	Other Non-Health
Reported in Process of Adjustment:										
1.1 Direct	1,942,425	375,091	0	0	0	0	1,567,334	0	0	0
1.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
1.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
1.4 Net	1,942,425	375,091	0	0	0	0	1,567,334	0	0	0
Incurred but Unreported:										
2.1 Direct	5,232,904	1,482,235	0	0	0	0	3,750,669	0	0	0
2.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
2.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
2.4 Net	5,232,904	1,482,235	0	0	0	0	3,750,669	0	0	0
Amounts Withheld from Paid Claims and Capitations:										
3.1 Direct	424,849	67,499	0	0	0	0	357,350	0	0	0
3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
3.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
3.4 Net	424,849	67,499	0	0	0	0	357,350	0	0	0
4. TOTALS:										
4.1 Direct	7,600,178	1,924,825	0	0	0	0	5,675,353	0	0	0
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
4.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
4.4 Net	7,600,178	1,924,825	0	0	0	0	5,675,353	0	0	0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

	Claims Paid D	Claim Reserve and Clair Claims Paid During the Year December 31 of Curre				6
	1	2	3	4		Estimated Claim Reserve and Claim
	On Claims Incurred Prior to January 1	On Claims Incurred	On Claims Unpaid December 31 of	On Claims Incurred	Claims Incurred In Prior Years	Liability December 31 of
Line of Business	of Current Year	During the Year	Prior Year	During the Year	(Columns 1 + 3)	Prior Year
Comprehensive (hospital and medical)	6,568,743	13,736,908	189,276	1,735,549	6,758,019	8,499,487
2. Medicare Supplement	0	0	0	0	0	0
3. Dental Only	0	0	0	0	0	0
4. Vision Only	0	0	0	0	0	0
5. Federal Employees Health Benefits Plan	0	0	0	0	0	0
6. Title XVIII - Medicare	3,858,489	45,653,988	61,964	5,613,389	3,920,453	3,775,106
7 Title XIX - Medicaid	0	0	0	0	0	0
8. Other health	0	0	0	0	0	0
9. Health subtotal (Lines 1 to 8)	10,427,232	59,390,896	251,240	7,348,938	10,678,472	12,274,593
10. Healthcare receivables (a)	0	1,074,180	0	0	0	984,011
11. Other non-health	0	0	0	0	0	0
12. Medical incentive pools and bonus amounts	627,598	475,462	0	471,545	627,598	0
13. Totals (Lines 9 - 10 + 11 + 12)	11,054,830	58,792,178	251,240	7,820,483	11,306,070	11,290,582

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Comprehensive (Hospital & Medical)

		Cumulative Net Amounts Paid						
		1	2	3	4	5		
	Year in Which Losses Were Incurred	2013	2014	2015	2016	2017		
1.	Prior	0	0	0	0	0		
2.	2013	0	0	0	0	0		
3.	2014	XXX	31,046	37,950	37,232	37 , 175		
4.	2015	XXX	XXX	33,411	37,366	37,524		
5.	2016	XXX	XXX	XXX	56,963	63,430		
6.	2017	XXX	XXX	XXX	XXX	13,737		

Section B - Incurred Health Claims - Comprehensive (Hospital & Medical)

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuse Outstanding at End of Year							
V · William W · L	1	1 2 3 4 5						
Year in Which Losses Were Incurred	2013	2014	2015	2016	2017			
1. Prior	0	0	0	0	0			
2. 2013	0	0	0	0	0			
3. 2014	XXX	38,853	38,209	37,239	37 , 175			
4. 2015	XXX	XXX	39,877	37,403	37,579			
5. 2016	XXX	XXX	XXX	65,419	63,564			
6. 2017	XXX	XXX	XXX	XXX	15,472			

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Comprehensive (Hospital & Medical)

	1	2	3	4	5	6	7	8	9	10
					Claim and Claim				Total Claims and	
Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1. 2013	0	0	0	0.0	0	0.0	0	0	0	0.0
2. 2014	47,759	37 , 175	354	1.0	37,529	78.6	0	0	37,529	78.6
3. 2015	39, 105	37,524	357	1.0	37,881	96.9	55	0	37,936	97.0
4. 2016	81,449	63,430	603	1.0	64,033	78.6	134	0	64 , 167	78.8
5. 2017	18,636	13,737	131	1.0	13,868	74.4	1,736	14	15,618	83.8

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

(\$000 Omitted) Section A - Paid Health Claims - Dental Only

	• • • • • • • • • • • • • • • • • • •	Cumulative Net Amounts Paid						
		1	2	3	4	5		
	Year in Which Losses Were Incurred	2013	2014	2015	2016	2017		
1.	Prior	0	(0	0	0		
2.	2013	3		5	5	5		
3.	2014	XXX	10	011	11	11		
4.	2015	XXX	XXX	0	0	0		
5.	2016	XXX	XXX	XXX	0	0		
6.	2017	XXX	XXX	XXX	XXX	0		

Section B - Incurred Health Claims - Dental Only

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuse Outstanding at End of Year							
Year in Which Losses Were Incurred	1 2 3 4 5 2013 2014 2015 2016 20							
real in Which Losses were incurred	2013	2014	2013	2010	2017			
1. Prior	0	0	0	0	0			
2. 2013	4	5	5	5	5			
3. 2014	XXX	11	11	11	11			
4. 2015	XXX	XXX	0	0	0			
5. 2016	XXX	XXX	XXX	0	0			
6. 2017	XXX	XXX	XXX	XXX	0			

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Dental Only

Years in which Premiums were Earned and Claims	1	2	3 Claim Adjustment	4 (Col. 3/2)	5 Claim and Claim Adjustment Expense Payments	(Col. 5/1)	7	8 Unpaid Claims Adjustment	9 Total Claims and Claims Adjustment Expense Incurred	10 (Col. 9/1)
were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1. 2013	9	5	0	0.0	5	55.6	0	0	5	55.6
2. 2014	16	11	0	0.0	11	68.8	0	0	11	68.8
3. 2015	0	0	0	0.0	0	0.0	0	0	0	0.0
4. 2016	0	0	0	0.0	0	0.0	0	0	0	0.0
5. 2017	0	0	0	0.0	0	0.0	0	0	0	0.0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Title XVIII

		Cumulative Net Amounts Paid							
		1	2	3	4	5			
	Year in Which Losses Were Incurred	2013	2014	2015	2016	2017			
1.	Prior	0	0	0	0	0			
2.	2013	1,146	1,314	1,302	1,302	1,302			
3.	2014	XXX	1,914	2,210	2,218	2,216			
4.	2015	XXX	XXX	19,799	21,947	21,982			
5.	2016	XXX	XXX	XXX	34,067	38,520			
6.	2017	XXX	XXX	XXX	XXX	46,129			

Section B - Incurred Health Claims - Title XVIII

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuse Outstanding at End of Year							
	1 2 3 4 5							
Year in Which Losses Were Incurred	2013	2014	2015	2016	2017			
1. Prior	0	0	0	0	0			
2. 2013	1,268	1,322	1,306	1,302	1,302			
3. 2014	XXX	2,223	2,234	2,218	2,216			
4. 2015	XXX	XXX	22,231	21,965	21,988			
5. 2016	XXX	XXX	XXX	37,823	38,576			
6. 2017	XXX	XXX	XXX	XXX	52,214			

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XVIII

	1	2	3	4	5	6	7	8	9	10
					Claim and Claim				Total Claims and	
Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1. 2013	1,790	1,302	12	0.9	1,314	73.4	0	0	1,314	73.4
2. 2014	2,713	2,216	21	0.9	2,237	82.5	0	0	2,237	82.5
3. 2015	27,480	21,982	209	1.0	22,191	80.8	6	0	22,197	80.8
4. 2016	47,233	38,520	366	1.0	38,886	82.3	56	0	38,942	82.4
5. 2017	58,622	46,129	439	1.0	46,568	79.4	6,085	45	52,698	89.9

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

(\$000 Omitted)

(\$000 Omitted) Section A - Paid Health Claims - Grand Total

	Cumulative Net Amounts Paid						
	1	2	3	4	5		
Year in Which Losses Were Incurred	2013	2014	2015	2016	2017		
1. Prior	0	0	0	0	0		
2. 2013	1,149	1,319	1,307	1,307	1,307		
3. 2014	XXX	32,970	40,171	39,461	39,402		
4. 2015	XXX	XXX	53,210	59,313	59,506		
5. 2016	XXX	XXX	XXX	91,030	101,950		
6. 2017	XXX	XXX	XXX	XXX	59,866		

Section B - Incurred Health Claims - Grand Total

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuse Outstanding at End of Year							
	1 2 3 4 5							
Year in Which Losses Were Incurred	2013	2014	2015	2016	2017			
1. Prior	0	0	0	0	0			
2. 2013	1,272	1,327	1,311	1,307	1,307			
3. 2014	XXX	41,087	40,454	39,468	39,402			
4. 2015	XXX	XXX	62,108	59,368	59,567			
5. 2016	XXX	XXX	XXX	103,242	102,140			
6. 2017	XXX	XXX	XXX	XXX	67,686			

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2013	1,799	1,307	12	0.9	1,319	73.3	0	0	1,319	73.3
2.	2014	50,488	39,402	375	1.0	39,777	78.8	0	0	39,777	78.8
3.	2015	66,585	59,506	566	1.0	60,072	90.2	61	0	60 , 133	90.3
4.	2016	128,682	101,950	969	1.0	102,919	80.0	190	0	103,109	80.1
5.	2017	77,258	59,866	570	1.0	60,436	78.2	7,821	59	68,316	88.4

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

		PART 2D - AC	GGREGATE RESER	VE FOR ACCIDENT	AND HEALTH CO	NTRACTS ONLY	•	1	1	
		1	Comprehensive	3 Medicare	Ponts Colin	Violes Carlo	6 Federal Employees Health	7 Title XVIII	8 Title XIX	9 Other
		Total	(Hospital & Medical)	Supplement	Dental Only	Vision Only	Benefits Plan	Medicare	Medicaid	Other
		0	0	0	0	0	0	0	0	0
2.	Additional policy reserves (a)	2,675,000	0	0	0	0	0	2,675,000	0	0
3.	Reserve for future contingent benefits	0	0	0	0	0	0	0	0	0
4.	Reserve for rate credits or experience rating refunds (including									
	\$0) for investment income	279,252	0	0	0	0	0	279,252	0	0
5.	Aggregate write-ins for other policy reserves	140,313	0	0	0	0	0	140,313	0	0
6.	Totals (gross)	3,094,565	0	0	0	0	0	3,094,565	0	0
7.	Reinsurance ceded	0	0	0	0	0	0	0	0	0
8.	Totals (Net)(Page 3, Line 4)	3,094,565	0	0	0	0	0	3,094,565	0	0
9.	Present value of amounts not yet due on claims	0	0	0	0	0	0	0	0	0
10.	Reserve for future contingent benefits	0	0	0	0	0	0	0	0	0
11.	Aggregate write-ins for other claim reserves	0	0	0	0	0	0	0	0	0
12.		0	0	0	0	0	0	0	0	0
13.	Reinsurance ceded	0	0	0	0	0	0	0	0	0
14.	Totals (Net)(Page 3, Line 7)	0	0	0	0	0	0	0	0	
	DETAILS OF WRITE-INS									
0501.	Risk Adjustment Premium Payable	140.313	0	0	0	0	0	140.313	0	0
0502.		, , , ,						, , , , , , , , , , , , , , , , , , , ,		
0503.										
0598.	Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	0
	Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	140.313	0	0	0	0	0	140.313	0	0
		,010		<u> </u>	<u> </u>			,010	,	
1102.										
1103.										
	Summary of remaining write-ins for Line 11 from overflow page		0	Λ	Λ	^	0	0	0	1
	Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above)		0	0	۰	0	0	0	0	
	. 544.5 (Line 1100 plac 1100) (Line 11 above)	l	U	U	U	1 0	1 0	1 0	1 0	1

(a) Includes \$ _____2,675,000 premium deficiency reserve.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 3 - ANALYSIS OF EXPENSES

			SIS OF EXPENSE			T
	-	Claim Adjustme 1	nt Expenses 2	3	4	5
		Cost Containment Expenses	Other Claim Adjustment Expenses	General Administrative Expenses	Investment Expenses	Total
1.	Rent (\$0 for occupancy of					
	own building)	72,850	21,313	146,672	281	241,116
2.	Salary, wages and other benefits	727,857	383,055	4,248,963	8, 162	5,368,037
3.	Commissions (less \$0		·			
	ceded plus \$ 0 assumed)		0	700.727	190	
4.	Legal fees and expenses				148	
5.	Certifications and accreditation fees					•
6.	Auditing, actuarial and other consulting services					
7.	Traveling expenses				193	
8.	Marketing and advertising				838	705.352
9.	Postage, express and telephone				608	, , , ,
	Printing and office supplies				170	
10.	Occupancy, depreciation and amortization			•	(11)	ĺ
11.						
12.	Equipment		23,043	136,377	304	260,684
13.	Cost or depreciation of EDP equipment and software	170,822	55,518	399,372	0	625,712
14.	Outsourced services including EDP, claims, and other services					
15.	Boards, bureaus and association fees					
16.	Insurance, except on real estate	8,946	2,635	18 , 184	35	29,800
17.	Collection and bank service charges	38,171	11,167	76,849	147	126,334
18.	Group service and administration fees	21,730	2,250	3,225	6	27,21
19.	Reimbursements by uninsured plans	0	0	0	0	
20.	Reimbursements from fiscal intermediaries	0	0	0	0	(
21.	Real estate expenses	52,517	15,365	105,736	202	173,820
22.	Real estate taxes	0	0	0	0	
23.	Taxes, licenses and fees:					
	23.1 State and local insurance taxes	0	0	(3, 199)	0	(3, 199
	23.2 State premium taxes	0	0	(1,876,296)	0	(1,876,296
	23.3 Regulatory authority licenses and fees	0	0	68,424	91	68,51
	23.4 Payroll taxes	0	0	246,858	474	247,332
	23.5 Other (excluding federal income and real estate taxes)	0	0	834,847	(1)	834,846
24.	Investment expenses not included elsewhere		2,949	(204,621)	(41)	(191,63
25.	Aggregate write-ins for expenses	47,689	13,953	7,659	159	69,460
26.	Total expenses incurred (Lines 1 to 25)	2.576.301	869,230	7,331,456	14,494	(a)10,791,48
27.			59,608	143,699	0	203,30
28.	' '	0	92,949	709,690	0	802,63
29.	Amounts receivable relating to uninsured plans, prior year	0	0	95,480	0	,
30.	Amounts receivable relating to uninsured plans, current year	0	0	61,328	0	61,32
31.	·	2,576,301	902,571	7,863,295	14,494	11,356,66
	DETAILS OF WRITE-INS	_,0.0,001	552,011	.,550,250	11,101	. 1,000,00
2501.	Miscellaneous Administrative Expenses	∆7 680	13,953	7,659	159	69,460
	·		10,800		139	
2502.						
2503.2598.	Summary of remaining write-ins for Line 25 from					
		0	0	0	0	
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	47,689	13,953 0 to nor	7,659	159	69,460

EXHIBIT OF NET INVESTMENT INCOME

		1	2
		Collected During Year	Earned During Year
1.	U.S. government bonds	(a)12,200	10,093
1.1	Bonds exempt from U.S. tax		0
1.2	Other bonds (unaffiliated)	(a)515,518	533,601
1.3	Bonds of affiliates	(a)0	0
2.1	Preferred stocks (unaffiliated)	(b)0	0
2.11	Preferred stocks of affiliates		
2.2	Common stocks (unaffiliated)	0	0
2.21	Common stocks of affiliates		
3.	Mortgage loans		0
4.	Real estate	(d)0	
5	Contract Loans		
6 7	Cash, cash equivalents and short-term investments		191,281
8.	Derivative instruments Other invested assets	` '	0
9.	Aggregate write-ins for investment income		0
10.	Total gross investment income	716.882	734,975
11.	Investment expenses	· · · · · · · · · · · · · · · · · · ·	
12.	Investment taxes, licenses and fees, excluding federal income taxes		
13.	Interest expense		
14.	Depreciation on real estate and other invested assets		` '
15.	Aggregate write-ins for deductions from investment income		* *
16.	Total deductions (Lines 11 through 15)		14,494
17.	Net investment income (Line 10 minus Line 16)		720,481
	DETAILS OF WRITE-INS		
0901.			
0902.			
0903.		_	_
0998.	Summary of remaining write-ins for Line 9 from overflow page	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)		0
1501.			
1502. 1503.			
1598.	Summary of remaining write-ins for Line 15 from overflow page		.0
1599.	Totals (Lines 1501 thru 1503 plus 1598) (Line 15, above)		0
1000.	Totals (Eines 1901) with 1900 plus 1990) (Eine 19, above)		
()	2.242	70	
(a) Incit	des \$3,243 accrual of discount less \$406,943 amortization of premium and less \$16,4	paid for accrued int	erest on purchases.
	des \$0 accrual of discount less \$0 amortization of premium and less \$		
(c) Inclu	des \$0 accrual of discount less \$	0 paid for accrued int	erest on purchases.
(d) Inclu	des \$	cumbrances.	
	des \$	70 paid for accrued int	erest on purchases.
	des \$0 accrual of discount less \$0 amortization of premium.		
	investment taxes, licenses and fees, excluding for regated and Separate Accounts.	ederal income taxes, att	ributable to

EXHIBIT OF CAPITAL GAINS (LOSSES)

	LAIIIDII		IAE GAIII	_ (=	,	_
		1	2	3	4	5
				Total Realized Capital	Change in	Change in Unrealized
		Realized Gain (Loss)	Other Realized	Gain (Loss)	Unrealized Capital	Foreign Exchange
		On Sales or Maturity	Adjustments	(Columns 1 + 2)	Gain (Loss)	Capital Gain (Loss)
1.	U.S. Government bonds	(14,823)		(14,823)		0
1.1	Bonds exempt from U.S. tax	0	0	0	0	0
1.2	Other bonds (unaffiliated)	(222,851)	0	(222,851)	1,567	0
1.3	Bonds of affiliates	0	0	0	0	0
2.1	Preferred stocks (unaffiliated)	0	0	0	0	0
2.11	Preferred stocks of affiliates	0	0	0	0	0
2.2	Common stocks (unaffiliated)	0	0	0	0	0
2.21	Common stocks of affiliates	0	0	0	0	0
3.	Mortgage loans	0	0	0	0	0
4.	Real estate		0	0	0	0
5.	Contract loans	0	0	0	0	0
6.	Cash, cash equivalents and short-term investments	0	0	0	0	0
7.	Derivative instruments	0	0	0	0	0
8.	Other invested assets	0	0	0	0	0
9.	Aggregate write-ins for capital gains (losses)	0	0	0	0	0
10.	Total capital gains (losses)	(237,674)	0	(237,674)	1,567	0
	DETAILS OF WRITE-INS					
0901.						
0902.						
0903.						
0998.	Summary of remaining write-ins for Line 9 from					
	overflow page	0	0	0	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9,					
	above)	0	0	0	0	0

EXHIBIT OF NON-ADMITTED ASSETS

		1	2	3 Chango in Total
		Current Year Total Nonadmitted Assets	Prior Year Total Nonadmitted Assets	Change in Total Nonadmitted Assets (Col. 2 - Col. 1)
1.	Bonds (Schedule D)	_	0	0
2.	Stocks (Schedule D):			
	2.1 Preferred stocks	0	0	0
	2.2 Common stocks	_	0	
3.	Mortgage loans on real estate (Schedule B):			
0.	3.1 First liens	0	0	0
	3.2 Other than first liens	_	0	0
4.	Real estate (Schedule A):			
٠.	4.1 Properties occupied by the company	0	0	0
	4.2 Properties held for the production of income.			0
	4.3 Properties held for sale		0	0
5.	Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments (Schedule DA)		0	0
6.	Contract loans		0	0
7.	Derivatives (Schedule DB)			
8.	Other invested assets (Schedule BA)			0
9.	Receivables for securities		0	0
10.	Securities lending reinvested collateral assets (Schedule DL)		0	
11.	Aggregate write-ins for invested assets			
12.	Subtotals, cash and invested assets (Lines 1 to 11)			
13.	Title plants (for Title insurers only)			
14.	Investment income due and accrued			
15.	Premiums and considerations:			
10.	15.1 Uncollected premiums and agents' balances in the course of collection	179 245	188 860	9 615
	15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due			
	15.3 Accrued retrospective premiums and contracts subject to redetermination		0	
16.	Reinsurance:		0	
10.	16.1 Amounts recoverable from reinsurers	0	0	0
	16.2 Funds held by or deposited with reinsured companies		0	
	16.3 Other amounts receivable under reinsurance contracts		0	0
17	Amounts receivable relating to uninsured plans		0	
				_
	Current federal and foreign income tax recoverable and interest thereon		0	(1,610,874)
	Net deferred tax asset			, , , ,
19.	Guaranty funds receivable or on deposit		0	
20.	Electronic data processing equipment and software		0	
21.	Furniture and equipment, including health care delivery assets			
22.	Net adjustment in assets and liabilities due to foreign exchange rates			
23.	Receivable from parent, subsidiaries and affiliates			
24.	Health care and other amounts receivable		585	
25.	Aggregate write-ins for other than invested assets	7,430,669	4,278,546	(3, 152, 123)
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)			
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts			
28.	Total (Lines 26 and 27)	9,891,461	5,136,705	(4,754,756)
	DETAILS OF WRITE-INS			
1101.				
1102.				
1103.				
1198.	Summary of remaining write-ins for Line 11 from overflow page		0	
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0
2501.	Provider Contracts		4,048,333	
2502.	Prepaid Commissions		81,386	
2503.	Deposits		148,827	
2598.	Summary of remaining write-ins for Line 25 from overflow page		0	
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	7,430,669	4,278,546	(3, 152, 123)

17

EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

EXHIBIT 1 - ENTICEEMENT BT 1 TIODOGT 1				<u> </u>		0
		2	Total Members at End of	4	<u>-</u>	0
Source of Enrollment	Prior Year	First Quarter	Second Quarter	4 Third Quarter	5 Current Year	Current Year Member Months
Health Maintenance Organizations	29,524	11,708	10,834	10,354	9,968	129,084
Provider Service Organizations	0	0	0	0	0	0
Preferred Provider Organizations	550	565	585	609	642	7,132
4. Point of Service	0	0	0	0	0	0
5. Indemnity Only	0	0	0	0	0	0
Aggregate write-ins for other lines of business	0	0	0	0	0	0
7. Total	30,074	12,273	11,419	10,963	10,610	136,216
DETAILS OF WRITE-INS						
0601.						
0602.						
0603.						
0698. Summary of remaining write-ins for Line 6 from overflow page	0	0	0	0	0	0
0699. Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	0	0	0	0	0

NOTES TO THE FINANCIAL STATEMENTS

1. Summary of Significant Accounting Policies and Going Concern

A. Accounting Practices

The financial statements of the Company are presented on the basis of accounting practices prescribed or permitted by the Michigan Department of Insurance.

The Michigan Department of Insurance recognizes only statutory accounting practices prescribed or permitted by the State of Michigan for determining and reporting the financial condition and results of operations of an insurance company, for determining its solvency under the Michigan Insurance Law. The National Association of Insurance Commissioners' (NAIC) Accounting Practices and Procedures manual (NAIC SAP) has been adopted as a component of prescribed or permitted practices by the State of Michigan. The Commissioner of Insurance has the right to permit other specific practices that deviate from prescribed practices. No deviations from the Codification currently exist.

A reconciliation of the Company's net income and capital and surplus between NAIC SAP and practices prescribed and permitted by the State of Michigan is shown below:

	SSAP #	F/S Page	F/S Line #		2017		2016
Net Loss		Č					
1. Humana Medical Plan of	XXX	XXX	XXX	\$	(2,045,387)	\$	(7,972,429)
Michigan, Inc. Michigan basis							
2. State Prescribed Practices that is							
an increase/(decrease) NAIC SAP					-		-
3. State Permitted Practices that is an							
increase/(decrease) NAIC SAP						_	
4. NAIC SAP	XXX	XXX	XXX	\$	(2,045,387)	\$_	(7,972,429)
Surplus							
5. Humana Medical Plan of	XXX	XXX	XXX	\$	24,332,983	\$	31,143,777
Michigan, Inc. Michigan basis							
6. State Prescribed Practices that is							
an increase/(decrease) NAIC SAP					-		-
7. State Permitted Practices that is an							
increase/(decrease) NAIC SAP				Φ	24 222 002	φ-	21 142 777
8. NAIC SAP	XXX	XXX	XXX	\$	24,332,983	\$_	31,143,777

On July 2, 2015, Humana entered into an Agreement and Plan of Merger, which is referred to herein as the Merger Agreement, with Aetna Inc. and certain wholly owned subsidiaries of Aetna Inc., (Aetna), which sets forth the terms and conditions under which Humana agreed to merge with, and become a wholly owned subsidiary of Aetna.

The Merger was subject to customary closing conditions, including, among other things, the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, the receipt of necessary approvals under state insurance and healthcare laws and regulations pursuant to certain licenses of certain Humana subsidiaries, and the absence of legal restraints and prohibitions on the consummation of the Merger.

On December 22, 2016, in order to extend the "End Date" (as defined in the Merger Agreement), Aetna and Humana each agreed to waive until 11:59 p.m. (Eastern time) on February 15, 2017 its right to terminate the Merger Agreement due to a failure of the Mergers to have been completed on or before December 31, 2016.

On July 21, 2016, the U.S. Department of Justice (DOJ) and the attorneys general of certain U.S. jurisdictions filed a civil antitrust complaint in the U.S. District Court for the District of Columbia against Humana and Aetna, alleging that the Merger would violate Section 7 of the Clayton Antitrust Act and seeking a permanent injunction to prevent the Merger from being completed. On January 23, 2017, the Court ruled in favor of the DOJ and granted a permanent injunction of the proposed transaction. On February 14, 2017, Humana and Aetna agreed to mutually terminate the Merger Agreement, as Humana's Board determined that an appeal of the Court's ruling would not be in the best interest of its stockholders. Under terms of the Merger Agreement, Humana received a breakup fee of \$1 billion on February 16, 2017.

B. Use of Estimates in the Preparation of the Financial Statements

The preparation of financial statements in conformity with Statutory Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. It also requires disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results could differ from those estimates.

C. Accounting Policy

Premiums are reported as earned in the period in which members are entitled to receive services, and are net of retroactive membership adjustments. Retroactive membership adjustments result from enrollment changes not yet processed, or not yet reported by an employer group or the government. Premiums received prior to such period are recorded as advance premiums.

Benefits incurred and loss adjustment expenses include claim payments, capitation payments, pharmacy costs net of rebates, allocations of certain centralized expenses, legal and administrative costs to settle claims, and various other costs incurred to provide health insurance coverage to members, as well as estimates of future payments to hospitals and others for medical care provided prior to the date of the statements of admitted assets, liabilities and surplus. Capitation payments represent monthly contractual fees disbursed to participating primary care physicians, and other providers who are responsible for providing medical care to members. Pharmacy costs represent payments for members' prescription drug benefits, net of rebates from drug manufacturers.

NOTES TO THE FINANCIAL STATEMENTS

In addition, the Company uses the following accounting policies:

- (1) Short-term investments include investments mainly in U.S. Government obligations with a maturity of twelve months or less from the date of purchase. Short-term investments are recorded at amortized cost. The carrying value of short-term investments approximates fair value due to the short-term maturities of the investments.
- (2-4) Investments are valued and classified in accordance with methods prescribed by the NAIC. Bonds with an NAIC rating of 1 or 2 are carried at amortized cost, with all other bonds being recorded at the lower of amortized cost or fair value; redeemable preferred stocks are carried at amortized cost; and non-redeemable preferred stocks are carried at fair value. Common stocks are carried at fair value.

The Company regularly evaluates investment securities for impairment. For all securities other than loan-backed and structured securities, the Company considers factors affecting the investee, factors affecting the industry the investee operates within, and general debt and equity market trends. The Company also considers the length of time an investment's fair value has been below carrying value, the near term prospects for recovery to carrying value, and the Company's intent and ability to hold the investment until maturity or market recovery is realized. If and when a determination is made that a decline in fair value below the cost basis is other-than-temporary, the related investment is written down to its estimated fair value through earnings.

Amortization of bond premium or discount is computed using the scientific interest method.

Income from investments is recorded on an accrual basis. For the purpose of determining realized gains and losses, the cost of securities sold is based upon specific identification. Investment income due and accrued over 90 days past due is nonadmitted.

- (5) Not Applicable.
- (6) For loan backed and structured securities where the securities fair value is less than the amortized cost, the Company considers several factors to determine if the security's impairment is other-than-temporary. If the Company has the intent to sell the security or if the Company does not have the intent and ability to retain the security until recovery of its fair value, the related investment is written down to its estimated fair value through earnings. If, however, the Company has the intent and ability to retain the security until recovery of its fair value, the Company considers factors affecting the investee, factors affecting the industry the investee operates within, and general debt and equity market trends. The Company also considers the length of time an investment's fair value has been below carrying value and the near term prospects for recovery to carrying value. If the determination is made, based on these factors, that the Company does expect to recover the entire amortized cost of the security, then an other-than-temporary impairment has not occurred. If, however, the determination is made that the Company does not expect to recover the entire amortized cost of the security based on the factors noted above, the Company recognizes a realized loss in earnings for the non-interest related decline. No loss is recognized for the interest impairment.
- (7) Not Applicable.
- (8) Not Applicable.
- (9) Not Applicable.
- (10-11) The estimates of future medical benefit payments are developed using actuarial methods and assumptions based upon claim payment patterns, medical cost inflation, historical development such as claim inventory levels and claim receipt patterns, and other relevant factors. Corresponding administrative costs to process outstanding claims are estimated and accrued. Estimates of future payments relating to services incurred in the current and prior periods are continually reviewed by management and adjusted as necessary.

The Company assesses the profitability of its contracts for providing health insurance coverage to its members when current operating results or forecasts indicate probable future losses. The Company records a premium deficiency liability in current operations to the extent that the sum of expected future medical costs, claim adjustment expenses and maintenance costs exceed related future premiums. Investment income is not contemplated in the calculation of the premium deficiency liability.

Management believes the Company's benefits payable and loss adjustment expense are adequate to cover future claims and loss adjustment expense payments required, however, such estimates are based on knowledge of current events and anticipated future events and, therefore, the actual liability could differ from the amounts provided.

(12) The Company has not modified its capitalization policy from the prior period.

Equipment is stated at cost less accumulated depreciation. Depreciation expense is computed using the straight-line method over estimated useful lives generally ranging from three to five years. Improvements to leased facilities are depreciated over the shorter of the remaining lease term or the anticipated life of the improvement.

The Company recognizes an asset or liability for the deferred tax consequences of temporary differences between the tax bases of assets or liabilities and their reported amounts in the financial statements. The temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled.

- (13) The Company estimates anticipated Pharmacy Rebate Receivables using the analysis of historical recovery patterns.
- (14) Not Applicable.

NOTES TO THE FINANCIAL STATEMENTS

(15) Not Applicable.

D. Going Concern

Effective December 31, 2016, the Company adopted revisions to SSAP No. 1, *Accounting Policies, Risks & Uncertainties, and Other Disclosures* (SSAP No. 1). The revisions require management of the Company to evaluate whether there is substantial doubt about the Company's ability to continue as a going concern and provide certain disclosures if substantial doubt exists. Management of the Company has completed its evaluation of the Company and determined that there is no substantial doubt about its ability to continue as a going concern.

2. Accounting Changes and Corrections of Errors

In April of 2017, the Company determined it was reasonably possible that two ongoing provider disputes related to plan years 2016 and 2017 would result in additional claims of \$290,101 and \$37,625, respectively. This resulted in the 2016 unpaid claims in liability, capital and surplus line 1 to be understated by \$290,101. The income statement, within hospital/medical benefits in the statement of revenue and expenses line 6, was also understated by the claims net of the tax impact of \$95,862. Consistent with SSAP No. 3, *Accounting Changes and Corrections of Errors* (SSAP No. 3), the net impact of the claims dispute for 2016 after the tax effect was recorded as an adjustment to surplus on line 47 of the statement of revenue and expenses capital and surplus account rollforward. The full amount of the 2016 and 2017 disputed claims were settled during the second quarter of 2017.

3. Business Combinations and Goodwill

A. Statutory Purchase Method

Not Applicable.

B. Statutory Merger

Not Applicable.

C. Assumption Reinsurance

Not Applicable.

D. Impairment Loss

Not Applicable.

4. <u>Discontinued Operations</u>

Not Applicable.

5. <u>Investments</u>

A. Mortgage Loans, Including Mezzanine Real Estate Loans

Not Applicable.

B. Debt Restructuring

Not Applicable.

C. Reverse Mortgages

Not Applicable.

- D. Loan-Backed Securities
 - Prepayment assumptions for mortgage-backed/loan-backed and structured securities were obtained from industry market sources.
 - (2) Not Applicable.
 - (3) Not Applicable.
 - (4) The Company does not have any investments in an other-than-temporary impairment position at December 31, 2017.

Gross unrealized losses and related fair value of temporarily impaired securities that have been in a continuous unrealized loss position were as follows at December 31, 2017:

 $(a) \quad \text{The aggregate amount of unrealized losses:} \\$

Ι.	Less than Twelve Months	\$ -
2.	Twelve Months or Longer	\$ (3,251)

(b) The aggregate related fair value of securities with unrealized losses:

1.	Less than Twelve Months	\$ -
2.	Twelve Months or Longer	\$ 78.847

NOTES TO THE FINANCIAL STATEMENTS

- (5) Unrealized losses are primarily due to increases in market interest rates and tighter liquidity conditions in the current markets than when the securities were purchased. All issuers of securities trading at an unrealized loss remain current on all contractual payments and the Company believes it is probable that all amounts due according to the contractual terms of the debt securities are collectible. After taking into account these and other factors, including the severity of the decline and the Company's ability and intent to hold these securities until recovery or maturity, the Company determined the unrealized losses on these investment securities were temporary and, as such, no impairment was required.
- E. Dollar Repurchase Agreements and/or Securities Lending Transactions
 - (1) The Company has no repurchase agreements or securities lending transactions.
 - (2) The Company has not pledged any of its assets as collateral.
 - (3-7) Not Applicable.
- F. Repurchase Agreements Transactions Accounted for as Secured Borrowing

Not Applicable.

G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing

Not Applicable.

H. Repurchase Agreements Transactions Accounted for as a Sale

Not Applicable.

I. Reverse Repurchase Agreements Transactions Accounted for as a Sale

Not Applicable.

J. Real Estate

Not Applicable.

K. Low-Income Housing Tax Credits (LIHTC)

Not Applicable.

- L. Restricted Assets
 - (1) Restricted Assets (Including Pledged)

	1	2	3	4	5	6	7
Restricted Asset Category	Total Gross (Admitted & Nonadmitted) Restricted from Current Year	Total Gross (Admitted & Nonadmitted) Restricted from Prior Year	Increase/ (Decrease) (1 minus 2)	Total Current Year Nonadmited Restricted	Total Current Year Admitted Restricted (1 minus 4)	Percentage Gross (Admitted & Nonadmitted) Restricted to Total Assets (a)	Percentage Admitted Restricted to Total Admitted Assets (b)
a. Subject to contractual							
obligation for which	\$ -	s -	s -	s -	\$ -	0/	0/
liability is not shown b. Collateral held under	\$ -	5 -	\$ -	\$ -	\$ -	-%	-%
security lending							
agreements	-	-	-	_	-	-	-
c. Subject to repurchase							
agreements	-	-	-	-	-	-	-
d. Subject to reverse							
repurchase agreements e. Subject to dollar	-	-	-	-	-	-	-
repurchase agreements	_	_	_	_	_	_	_
f. Subject to dollar reverse							
repurchase agreements	-	-	-	-	-	-	-
g. Placed under option							
contracts	-	-	-	-	-	-	-
h. Letter stock or securities restricted to sale –							
excluding FHLB							
capital stock	-	_	_	_	_	_	_
i. FHLB capital							
stock	-	-	-	-	-	-	-
j. On deposit with states	1,003,043	1,008,847	(5,804)	-	1,003,043	2.02%	2.52%
k. On deposit with other regulatory bodies							
l. Pledged collateral to	-	-	-	-	-	-	-
FHLB (including							
assets backing funding							
agreements)	-	-	-	-	-	-	-
m. Pledged as collateral not							
captured in other							
categories n. Other restricted assets	-	-	-	-	_	-	-
o. Total Restricted Assets	\$ 1,003,043	\$ 1,008,847	\$ (5,804)		\$ 1,003,043	2.02%	2.52%
	, ,,,,,,,,,	. ,,	. (- , , , ,		. ,,		

NOTES TO THE FINANCIAL STATEMENTS

(2) Detail of Assets Pledged as Collateral Not Captured in Other Categories (Contracts that Share Similar Characteristics, Such as Reinsurance and Derivatives, Are Reported in the Aggregate)

Not Applicable.

(3) Detail of Other Restricted Assets Categories (Contracts that Share Similar Characteristics, Such as Reinsurance and Derivatives, Are Reported in the Aggregate)

Not Applicable.

(4) Collateral Received and Reflected as Assets Within the Reporting Entity's Financial Statements

Not Applicable.

M. Working Capital Finance Investments

Not Applicable.

N. Offsetting and Netting of Assets and Liabilities

Not Applicable.

O. Structured Notes

Not Applicable.

P. 5* Securities

Not Applicable.

O. Short Sales

Not Applicable.

R. Prepayment Penalty and Acceleration Fees

General Account

- (1) Number of CUSIPS
- (2) Aggregate Amount of Investment Income

\$

3

6. <u>Joint Ventures, Partnerships and Limited Liability Companies</u>

- A. The Company has no investments in Joint Ventures, Partnerships or Limited Liability Companies that exceed 10.0 percent of its admitted assets.
- B. The Company did not recognize any impairment write down for its investments in Joint Ventures, Partnerships and Limited Liability Companies during the statement periods.

7. <u>Investment Income</u>

A. Due and accrued income was excluded from surplus on the following basis:

All investment income due and accrued with amounts that are over 90 days past due with the exception of mortgage loans in default.

B. The total amount excluded was \$0.

8. <u>Derivative Instruments</u>

Not Applicable.

9. <u>Income Taxes</u>

A. Deferred Tax Assets/(Liabilities)

(1) The components of the net admitted deferred tax asset/(liability) by tax character were as follows:

		D	ecem	ber 31, 2017	
		Ordinary		Capital	Total
a.	Gross deferred tax assets	\$ 2,281,295	\$	912	\$ 2,282,207
b.	Statutory valuation allowance adjustments	 -		(912)	(912)
c.	Adjusted gross deferred tax assets	 2,281,295		-	2,281,295
d.	Deferred tax assets nonadmitted	(2,279,588)		-	(2,279,588)
e.	Net admitted deferred tax assets	 1,707		-	1,707
f.	Deferred tax liabilities	(1,707)		-	(1,707)
g.	Net admitted deferred tax asset/(liability)	\$ -	\$	-	\$ -

NOTES TO THE FINANCIAL STATEMENTS

		D	ecen	nber 31, 2016	
		Ordinary		Capital	Total
a.	Gross deferred tax assets	\$ 2,102,832	\$	2,069	\$ 2,104,901
b.	Statutory valuation allowance adjustments	-		(2,069)	(2,069)
c.	Adjusted gross deferred tax assets	 2,102,832		-	2,102,832
d.	Deferred tax assets nonadmitted	 (668,714)		-	(668,714)
e.	Net admitted deferred tax assets	1,434,118		-	1,434,118
f.	Deferred tax liabilities	(5,265)		-	(5,265)
g.	Net admitted deferred tax asset/(liability)	\$ 1,428,853	\$	-	\$ 1,428,853
			(Change	
		 Ordinary	(Change Capital	Total
a.	Gross deferred tax assets	\$ Ordinary 178,463	\$	\mathcal{C}	\$ Total 177,306
a. b.	Gross deferred tax assets Statutory valuation allowance adjustments	\$ -		Capital	\$
		\$ -		Capital (1,157)	\$ 177,306
b.	Statutory valuation allowance adjustments	\$ 178,463		Capital (1,157)	\$ 177,306 1,157
b. c.	Statutory valuation allowance adjustments Adjusted gross deferred tax assets	\$ 178,463 - 178,463		Capital (1,157)	\$ 177,306 1,157 178,463
b. c. d.	Statutory valuation allowance adjustments Adjusted gross deferred tax assets Deferred tax assets nonadmitted	\$ 178,463 - 178,463 (1,610,874)		Capital (1,157)	\$ 177,306 1,157 178,463 (1,610,874)
b. c. d. e.	Statutory valuation allowance adjustments Adjusted gross deferred tax assets Deferred tax assets nonadmitted Net admitted deferred tax assets	\$ 178,463 - 178,463 (1,610,874) (1,432,411)		Capital (1,157)	\$ 177,306 1,157 178,463 (1,610,874) (1,432,411)

(2) The amount of admitted adjusted gross deferred tax assets under SSAP No. 101 were as follows:

		 Ordinary	Dece	ember 31, 201 Capital	7	Total
a. b.	Federal income taxes paid in prior years recoverable through loss carrybacks Adjusted gross deferred tax assets expected to be realized after application of the	\$ -	\$	-	\$	-
1.	to be realized following the Balance Sheet date	XXX		XXX		-
c.	per limitation threshold Adjusted gross deferred tax assets offset by	XXX		XXX		3,649,947
	gross deferred tax liabilities	 1,707				1,707
d.	Deferred tax assets admitted as the result of application of SSAP No. 101. Total	\$ 1,707	\$	-	\$	1,707
		 Ordinary	Dece	ember 31, 201 Capital	6	Total
a. b.	Federal income taxes paid in prior years recoverable through loss carrybacks Adjusted gross deferred tax assets expected	\$ 873,853	\$	-	\$	873,853
1.	to be realized after application of the threshold limitation Adjusted gross deferred tax assets expected	555,000		-		555,000
2.	to be realized following the Balance Sheet date Adjusted gross deferred tax assets allowed	XXX		XXX		555,000
c.	per limitation threshold Adjusted gross deferred tax assets offset by	XXX		XXX		4,457,239
	gross deferred tax liabilities	 5,265		-		5,265
d.	Deferred tax assets admitted as the result of application of SSAP No. 101. Total	\$ 1,434,118	\$	-	\$	1,434,118
		Ordinary		Change Capital		Total
a. b.	Federal income taxes paid in prior years recoverable through loss carrybacks Adjusted gross deferred tax assets expected	\$ (873,853)	\$	-	\$	(873,853)
1.	3 &	(555,000)		-		(555,000)
2.	to be realized following the Balance Sheet date Adjusted gross deferred tax assets allowed	XXX		XXX		(555,000)
c.	per limitation threshold Adjusted gross deferred tax assets offset by	XXX		XXX		(807,292)
	gross deferred tax liabilities	 (3,558)		-		(3,558)
d.	Deferred tax assets admitted as the result of application of SSAP No. 101. Total	\$ (1,432,411)	\$	-	\$	(1,432,411)

(3) The ratio percentage used to determine recovery period and threshold limitation amount was as follows:

		December 31, 2017	December 31, 2010
a.	Ratio percentage used to determine recovery period		
	and threshold limitation amount	842%	682%
b.	Amount of adjusted capital and surplus used to		
	determine recovery period and threshold limitation		
	in 2 b.2 above	24,332,983	29,714,924

NOTES TO THE FINANCIAL STATEMENTS

(4) The impact of tax planning strategies on adjusted gross DTAs and net admitted DTAs was as follows:

	Decem Ordinary	ber 31, 2	2017 Capital
a. Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage	Orumary		Cupitar
1. Adjusted gross DTAs amount from note 9A1(c)	\$ 2,281,295	\$	-
2. Percentage of adjusted gross DTAs by tax character attributable to the impact of tax planning strategies	0.00%		0.00%
 Net admitted adjusted gross DTAs amount from note 9A1(e) 	\$ 1,707	\$	-
 Percentage of net admitted adjusted gross DTAs by tax character admitted because of the impact of tax planning 			
strategies	0.00%		0.00%
	Decem Ordinary	ber 31, 2	2016 Capital
a. Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage	J		•
1. Adjusted gross DTAs amount from note 9A1(c)	\$ 2,102,832	\$	-
Percentage of adjusted gross DTAs by tax character attributable to the impact of tax planning strategies Not admitted adjusted gross DTAs amount from notes.	0.00%		0.00%
 3. Net admitted adjusted gross DTAs amount from note 9A1(e) 4. Percentage of net admitted adjusted gross DTAs by tax 	\$ 1,434,118	\$	-
character admitted because of the impact of tax planning strategies	0.00%		0.00%
		Change	
Determination of directed array defermed to a contract and not	 Ordinary		Capital
Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage			
1. Adjusted gross DTAs amount from note 9A1(c)	\$ 178,463	\$	-
2. Percentage of adjusted gross DTAs by tax character attributable to the impact of tax planning strategies	0.00%		0.00%
 3. Net admitted adjusted gross DTAs amount from note 9A1(e) 4. Percentage of net admitted adjusted gross DTAs by tax 	\$ (1,432,411)	\$	-
character admitted because of the impact of tax planning strategies	0.00%		0.00%

- b. Does the Company's tax planning strategies include the use of reinsurance? Yes $[]$ No $[]$
- B. There are no temporary differences for which a DTL has not been established.
- C. Current and deferred income taxes
 - (1) Current income taxes incurred consist of the following major components:

		December	December	
		 31, 2017	31, 2016	Change
a.	Federal	\$ (212,862) \$	(3,181,014) \$	2,968,152
b.	Foreign	-	-	
c.	Subtotal	(212,862)	(3,181,014)	2,968,152
d.	Federal income tax on net capital gains	(83,186)	(34,155)	(49,031)
e.	Utilization of capital loss			
	carryforwards	-	-	-
f.	Other	2,421	(1,821)	4,242
g.	Federal and foreign income taxes			
	incurred	\$ (293,627) \$	(3,216,990) \$	2,923,363

NOTES TO THE FINANCIAL STATEMENTS

(2–3) The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities are as follows:

DTAs resulting from Book/Tax Differences in:

a.	ulting from Book/Tax Differences in: Ordinary	 December 31, 2017	December 31 2016	,	Change
	1. Discounting of unpaid losses	\$ 711,736	\$ 454,259	\$	257,477
	2. Unearned premium reserve	56,550	120,675		(64,125)
	3. Policyholder reserves	-	-		-
	4. Investments and other	-	-		-
	5. Deferred acquisition costs	-	-		-
	6. Policyholder dividends accrual	-	-		-
	7. Fixed assets	-	-		-
	8. Compensation and benefit accruals	-	-		-
	9. Pension accruals	-	-		-
	10. Receivables – nonadmitted	-	-		-
	11. Net operating loss carry-forward	-	-		-
	12. Tax credit carry-forward	-	-		-
	13. Other	-	-		-
	14. Bad debts	1,076	2,144		(1,068)
	15. Accrued litigation	-	-		-
	16. CMS Rx reserve	550	111		439
	17. CMS risk corridor -ACA	-	-		
	18. Medicare risk adjustment data	-	-		
	19. Miscellaneous reserves	539	27		512
	20. Accrued lease	-	-		
	21. Section 197 intangible	-	-		-
	22. Reinsurance fee	-	56,637		(56,637)
	23. Provider contracts	 1,510,844	1,468,979		41,865
	99. Subtotal	2,281,295	2,102,832		178,463
	Statutory valuation allowance				
	adjustment	(2.270.500)	(((0.714)		(1 (10 074)
	Nonadmitted	 (2,279,588)	(668,714)		(1,610,874)
	Admitted Ordinary DTAs	 1,707	1,434,118		(1,432,411)
	Capital	0.1.0	• 0.00		(4.4.5=)
	1. Investments	912	2,069		(1,157)
	2. Net capital loss carry-forward	-	-		-
	3. Real estate	-	-		-
	4. Other	 -	-		-
	99. Subtotal	912	2,069		(1,157)
	Statutory valuation allowance adjustment	(912)	(2,069)		1,157
•	Nonadmitted	 -	-		
	Admitted capital DTAs	 -			-
	Admitted DTAs	\$ 1,707	\$ 1,434,118	\$	(1,432,411)

DTLs

(4)

a.	ulting from Book/Tax Differences in: Ordinary	 December 31, 2017	December 31, 2016	Change
	1. Investments	\$ -	\$ -	\$ -
	2. Fixed assets3. Deferred and uncollected	-	-	-
	premium 4. Policyholder reserves/salvage & subrogation	-	-	-
	5. Other	-	-	-
	6. Premium acquisition reserve	(1,707)	(5,265)	3,558
	7. CMS RX Reserve	-	-	-
	8. Accrued Leases	-	-	
	99. Subtotal	(1,707)	(5,265)	3,558
b.	Capital			
	1. Investments	-	-	-
	2. Real estate	-	-	-
	3. Other	-	-	
	99. Subtotal	-	-	
c.	DTLs	\$ (1,707)	\$ (5,265)	\$ 3,558
Ne	t deferred tax asset/(liability)	\$ 	\$ 1,428,853	\$ (1,428,853)

NOTES TO THE FINANCIAL STATEMENTS

The tax reform law enacted on December 22, 2017 (the "Tax Reform Law") reduced the statutory federal corporate income tax rate to 21 percent from 35 percent, beginning in 2018. The rate reduction required a remeasurement of the Company's net deferred tax asset. This impact on surplus is as follows:

	 Surplus Impact
Tax Reform Effect on Operations	\$ (1,519,725)
Tax Reform Effect on Deferred Taxes Non-Admitted	1,519,725
Tax Reform Effect on Unrealized Gains and Losses	
Total Impact of Tax Reform	\$ _

D. The provision for federal income taxes incurred is different from that which would be obtained by applying the statutory Federal income tax rate to income before income taxes. The significant items causing this difference as of December 31, 2017 are as follows:

	Amount	Tax Effect	Effective Tax Rate
Income before taxes	\$ (2,339,014)	\$ (818,655)	35.00%
Tax-exempt interest	(231,416)	(80,996)	3.46%
Dividends received deduction	-	-	0.00%
Proration	34,712	12,149	(0.52%)
Meals & entertainment, lobbying expenses, etc.	9,197	3,219	(0.14%)
Statutory valuation allowance adjustment	-	-	0.00%
Provider Disputed Claims	(290,101)	(101,535)	4.34%
Tax Reform Change to Nonadmitted Assets & Deferred tax	-	1,519,725	(64.97%)
true-up	(3,143,877)	(1,100,357)	47.04%
Other, including prior year true-up	 7,780	2,723	(0.12%)
Total	\$ (5,952,719)	\$ (563,727)	24.09%
Federal income taxes incurred [expense/(benefit)]		\$ (210,441)	9.00%
Tax on capital gains/(losses) Change in net deferred income tax		(83,186)	3.56%
[charge/(benefit)]		(182,021)	7.76%
Correction of prior period error		 (88,079)	3.77%
Total statutory income taxes		\$ (563,727)	24.09%

E. Operating loss and tax credit carry-forwards and protective tax deposits

At December 31, 2017, the Company had no net operating loss carry-forwards.

At December 31, 2017, the Company had no capital loss carry-forwards.

At December 31, 2017, the Company had no AMT credit carry-forwards.

(2) The following table demonstrates the income tax expense for 2015, 2016 and 2017 that is available for the recoupment in the event of future net losses:

	Ordinary	Capital	Total	
2015	\$ -	\$ -	\$	-
2016	-	-		-
2017	-	-		-
Total	\$ -	\$ -	\$	-

- (3) There are no deposits admitted under IRC § 6603.
- F. The Company is included in a consolidated federal income tax return with its parent Company, Humana Inc. The Company has a written agreement, approved by the Company's Board of Directors, which sets forth the manner in which the total combined federal income tax is allocated to each entity which is a party to the consolidation. Pursuant to this agreement, the Company has the enforceable right to be paid for any future net losses it may incur. The Company has no contingent income tax liabilities. The Company has not adjusted gross deferred tax assets due to changes in judgment about the realizability of the related deferred tax asset. The Company has no deposits under Section 6603 of the Internal Revenue Code.

NOTES TO THE FINANCIAL STATEMENTS

HUMANA INC. AND SUBSIDIARIES INCLUDED IN 2017 CONSOLIDATED FEDERAL INCOME TAX RETURN

CALENDAR YEAR ENDED DECEMBER 31, 2017 AFFILIATIONS SCHEDULE

CORPORATE NAME AND EMPLOYER IDENTIFICATION NUMBER THE ADDRESS OF EACH COMPANY IS: P. O. BOX 740026, LOUISVILLE, KY 40201

		EMPLOYER
CORP.	,	IDENTIFICATION
NO.	CORPORATION NAME	NUMBER
1	HUMANA INC.	61-0647538
2	154TH STREET MEDICAL PLAZA, INC.	65-0851053
3	516-526 WEST MAIN STREET CONDOMINIUM COUNCIL OF CO-OWNERS INC.	5, 20-5309363
4	54TH STREET MEDICAL PLAZA, INC.	65-0293220
5	AMERICAN ELDERCARE, INC.	65-0380198
6	ARCADIAN HEALTH PLAN, INC.	20-1001348
7	CAC MEDICAL CENTER HOLDINGS, INC.	30-0117876
8	CAC-FLORIDA MEDICAL CENTERS, LLC	26-0010657
9	CARENETWORK, INC.	39-1514846
10	CAREPLUS HEALTH PLANS, INC.	59-2598550
11	CARITEN HEALTH PLAN INC.	62-1579044
12	CHA HMO, INC.	61-1279717
13	CHA SERVICE COMPANY, INC.	61-1279716
14	COMPBENEFITS COMPANY	59-2531815
15	COMPBENEFITS CORPORATION	04-3185995
16	COMPBENEFITS DENTAL, INC.	36-3686002
17	COMPBENEFITS DIRECT, INC.	58-2228851
18	COMPBENEFITS INSURANCE COMPANY	74-2552026
19	COMPLEX CLINICAL MANAGEMENT, INC.	45-3713941
20	COMPREHENSIVE HEALTH INSIGHTS, INC.	42-1575099
21	CONTINUCARE CORPORATION	59-2716023
22	CONTINUCARE MEDICAL MANAGEMENT, INC.	65-0791417
23	CONTINUCARE MSO, INC.	65-0780986
24	CORPHEALTH PROVIDER LINK, INC.	20-8236655
25	DATALINK SOLUTIONS, INC.	47-4706668
26	DEFENSEWEB TECHNOLOGIES, INC.	33-0916248
27	DENTAL CARE PLUS MANAGEMENT, CORP.	36-3512545
28	DENTICARE, INC.	76-0039628
29	EMPHESYS INSURANCE COMPANY	31-0935772
30	EMPHESYS, INC.	61-1237697
31	HARRIS, ROTHENBERG INTERNATIONAL, INC.	27-1649291
32	HEALTH VALUE MANAGEMENT, INC.	61-1223418
33	HUMANA EAP AND WORK-LIFE SERVICES OF CALIFORNIA, INC. (fka HRI HUMANA OF CALIFORNIA, INC.)	46-4912173
34	HUMANA ACTIVE OUTLOOK, INC.	20-4835394
35	HUMANA AT HOME (DALLAS), INC.	75-2739333
36	HUMANA AT HOME (HOUSTON), INC.	76-0537878
37	HUMANA AT HOME (MA), INC.	04-3580066
38	HUMANA AT HOME (SAN ANTONIO), INC.	01-0766084
39	HUMANA AT HOME (TLC), INC.	75-2600512
40	HUMANA AT HOME 1, INC.	65-0274594
41	HUMANA AT HOME, INC.	13-4036798
42	HUMANA BEHAVIORAL HEALTH, INC.	75-2043865
43	HUMANA BENEFIT PLAN OF ILLINOIS, INC.	37-1326199
44	HUMANA DENTAL COMPANY	59-1843760
45	HUMANA DENTAL CONCERN, LTD.	36-3654697
46	HUMANA EMPLOYERS HEALTH PLAN OF GEORGIA, INC.	58-2209549
47	HUMANA GOVERNMENT BUSINESS, INC.	61-1241225
48	HUMANA HEALTH BENEFIT PLAN OF LOUISIANA, INC.	72-1279235
49	HUMANA HEALTH COMPANY OF NEW YORK, INC.	26-2800286
50	HUMANA HEALTH INSURANCE COMPANY OF FLORIDA, INC.	61-1041514
51	HUMANA HEALTH PLAN OF CALIFORNIA, INC.	26-3473328
52	HUMANA HEALTH PLAN OF OHIO, INC.	31-1154200
5.2	HUMANIA HEALTH DI AN OFTEVACINO	(1.0004(22

61-0994632

53 HUMANA HEALTH PLAN OF TEXAS, INC.

NOTES TO THE FINANCIAL STATEMENTS

54	HUMANA HEALTH PLAN, INC.	61-1013183
55	HUMANA HOME ADVANTAGE (TX), P.A.	81-0789608
56	HUMANA INNOVATION ENTERPRISES, INC.	61-1343791
57	HUMANA INSURANCE COMPANY	39-1263473
58	HUMANA INSURANCE COMPANY OF KENTUCKY	61-1311685
59	HUMANA INSURANCE COMPANY OF NEW YORK	20-2888723
60		61-1343508
61	HUMANA MARKETPOINT, INC.	27-3991410
	HUMANA MEDICAL PLAN OF MICHIGAN, INC.	
62 63	HUMANA MEDICAL PLAN OF PENNSYLVANIA, INC. HUMANA MEDICAL PLAN OF UTAH, INC.	27-4460531 20-8411422
64	•	61-1103898
65	HUMANA MEDICAL PLAN, INC.	45-2254346
	HUMANA PHARMACY SOLUTIONS, INC.	61-1316926
66	HUMANA PEGIONAL HEALTH PLAN INC	
67	HUMANA REGIONAL HEALTH PLAN, INC.	20-2036444
68	HUMANA VETERANS HEALTHCARE SERVICES, INC. HUMANA WISCONSIN HEALTH ORGANIZATION INSURANCE	20-8418853
69	CORPORATION	39-1525003
70	HUMANADENTAL INSURANCE COMPANY	39-0714280
71	HUMANADENTAL, INC.	61-1364005
72	HUMCO, INC.	61-1239538
73	HUM-e-FL, INC.	61-1383567
74	KANAWHA INSURANCE COMPANY	57-0380426
75	KMG AMERICA CORPORATION	20-1377270
76	MANAGED CARE INDEMNITY, INC.	61-1232669
77	METCARE OF FLORIDA, INC.	65-0879131
78	METROPOLITAN HEALTH NETWORKS, INC.	65-0635748
79	PARTNERS IN INTEGRATED CARE, INC.	47-2905609
80	PARTNERS IN PRIMARY CARE (KS), P.A.	82-2000699
81	PARTNERS IN PRIMARY CARE (NC), P.C.	82-1926920
82	PARTNERS IN PRIMARY CARE OF ILLINOIS, P.C.	45-4041098
83	PARTNERS IN PRIMARY CARE, P.A.	47-1161014
84	PHP COMPANIES, INC.	62-1552091
85	PREFERRED HEALTH PARTNERSHIP, INC.	62-1250945
86	PRESERVATION ON MAIN, INC.	20-1724127
87	PRIMARY CARE HOLDINGS, INC.	46-1225873
88	ROHC, LLC	75-2844854
89	SENIORBRIDGE (NC), INC.	56-2593719
90	SENIORBRIDGE CARE MANAGEMENT, INC.	80-0581269
91	SENIORBRIDGE FAMILY COMPANIES (AZ), INC.	46-0702349
92	SENIORBRIDGE FAMILY COMPANIES (CA), INC.	45-3039782
93	SENIORBRIDGE FAMILY COMPANIES (CT), INC.	27-0452360
94	SENIORBRIDGE FAMILY COMPANIES (FL), INC.	65-1096853
95	SENIORBRIDGE FAMILY COMPANIES (IL), INC.	02-0660212
96	SENIORBRIDGE FAMILY COMPANIES (MD), INC.	81-0557727
97	SENIORBRIDGE FAMILY COMPANIES (MO), INC.	46-0677759
98	SENIORBRIDGE FAMILY COMPANIES (NJ), INC.	36-4484449
99	SENIORBRIDGE FAMILY COMPANIES (NY), INC.	36-4484443
100	SENIORBRIDGE FAMILY COMPANIES (OH), INC.	20-0260501
101	SENIORBRIDGE FAMILY COMPANIES (PA), INC.	38-3643832
102	SENIORBRIDGE FAMILY COMPANIES (VA), INC.	46-0691871
103	TEXAS DENTAL PLANS, INC.	74-2352809
104	THE DENTAL CONCERN, INC.	52-1157181
105	TRANSCEND COMMUNITY PHYSICIAN NETWORK (AR), P.A.	47-2770181
106	TRANSCEND COMMUNITY PHYSICIAN NETWORK (KS), P.A.	47-2111323
107	TRANSCEND COMMUNITY PHYSICIAN NETWORK, P.C.	47-2750105
108	TRANSCEND INSIGHTS, INC.	80-0072760
109	TRANSCEND POPULATION HEALTH MANAGEMENT, LLC	46-5329373

G. The Company does not have any tax loss contingencies for which it is reasonably possible that the total liability will significantly increase within twelve months of the reporting date.

NOTES TO THE FINANCIAL STATEMENTS

10. Information Concerning Parent, Subsidiaries and Affiliates

A.-F. The Company has several management contracts with Humana Inc. and other related parties whereby the Company is provided with medical and executive management, information systems, claims processing, billing and enrollment, and telemarketing and other services as required by the Company. Management fees charged to operations for the years ended December 31, 2017 and 2016 were \$8,998,859 and \$13,069,267, respectively. As a part of this agreement, the Company makes cash disbursements on behalf of the Company which includes, but is not limited to, medical related items, general and administrative expenses, commissions and payroll. Humana Inc. is reimbursed by the Company weekly, based upon historical pattern of amounts and timing. Each month, these estimates are adjusted to ultimately settle upon actual disbursements made on behalf of the Company. The Company continues to be primarily liable for any outstanding payments made on behalf of the Company, should Humana Inc. not be able to fulfill its obligations.

No dividends were paid by the Company as of December 31, 2017.

At December 31, 2017, the Company reported \$3,153,650 due from Humana Inc. Amounts due to or from parent are generally settled within 30 days.

- G. All outstanding shares of the Company are owned by the Parent Company.
- H. Not Applicable.
- I. Not Applicable.
- J. Not Applicable.
- K. Not Applicable.
- L. Not Applicable.
- M. Not Applicable.
- N. Not Applicable

11. <u>Debt</u>

A. Debt Including Capital Notes

The Company has no debentures outstanding.

The Company has no capital notes outstanding.

The Company does not have any reverse repurchase agreements.

B. Federal Home Loan Bank (FHLB) Agreements

The Company does not have any FHLB agreements.

- 12. <u>Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans</u>
 - A.-D. Defined Benefit Plans

Not Applicable.

E. Defined Contribution Plans

Not Applicable.

F. Multiemployer Plans

Not Applicable.

G. Consolidated/Holding Company Plans

The Company employees are eligible to participate in the Humana Retirement and Savings Plan ("the Plan"), a defined contribution plan, sponsored by Humana Inc. The Plan maintains two accounts, the Savings Account and the Retirement Account.

Humana Inc.'s total contributions paid to the Savings and Retirement accounts of the Humana Retirement Savings Plan were \$216,450,717 and \$193,755,632 for the years ended December 31, 2017 and 2016, respectively. As of December 31, 2017 and 2016, the fair market value of the Humana Retirement Savings Plan's assets was \$4,638,342,913 and \$3,900,036,594, respectively.

H. Postemployment Benefits and Compensated Absences

Not Applicable.

NOTES TO THE FINANCIAL STATEMENTS

I. Impact of Medicare Modernization Act on Postretirement Benefits (INT 04-17)

Not Applicable.

13. Capital and Surplus, Shareholders' Dividend Restrictions and Quasi-Reorganizations

- (1) The Company has \$1 par value common stock with 1,000 shares authorized and 1,000 shares issued and 1,000 outstanding. All shares are common stock shares.
- (2) The Company has no preferred stock outstanding.
- (3-5) Dividends and returns of capital to shareholders are noncumulative and are paid as determined by the Board of Directors. In accordance with the Michigan Department of Insurance statutes, the maximum amount which can be paid by the Company to shareholders without prior approval by the Michigan Department of Insurance is the greater of 10% of total surplus or net gain from operations from the prior year. Ordinary dividends are limited to available and accumulated surplus funds from the prior year. Based on these restrictions, no dividend was available without prior approval.

Within the limitations above, there are no restrictions placed on the portion of Company profits that may be paid as ordinary dividends to stockholders.

No dividends were paid by the Company as of December 31, 2017.

- (6) There were no restrictions placed on the Company's surplus, including for whom the surplus is being held.
- (7) Not Applicable.
- (8) Not Applicable.
- (9) Changes in balances of special surplus funds from the prior year is due to the estimated health insurance industry fee that will be payable on September 30, 2018.
- (10) The portion of unassigned funds (surplus) represented or reduced by cumulative unrealized gains and losses is \$1,567.
- (11) Not Applicable.
- (12) Not Applicable.
- (13) Not Applicable.

14. <u>Liabilities, Contingencies and Assessments</u>

A. Contingent Commitments

Not Applicable.

B. Assessments

Not Applicable.

C. Gain Contingencies

Not Applicable.

D. Claims related extra contractual obligation and bad faith losses stemming from lawsuits

Not Applicable.

E. Joint and Several Liabilities

Not Applicable.

F. All Other Contingencies

During the ordinary course of business, the Company is subject to pending and threatened legal actions. Management of the Company does not believe that any of these actions will have a material adverse effect on the Company's surplus, results of operations or cash flows. However, the likelihood or outcome of current or future legal proceedings cannot be accurately predicted, and they could adversely affect the Company's surplus, results of operations and cash flows.

The Company is not aware of any other material contingent liabilities as of December 31, 2017.

15. Leases

Not Applicable.

16. <u>Information about Financial Instruments With Off-Balance Sheet Risk and Financial Instruments With Concentrations of Credit Risk</u>

The Company has no investment in Financial Instruments with Off-Balance Sheet Risk or Concentrations of Credit Risk.

NOTES TO THE FINANCIAL STATEMENTS

17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities

A. Transfers of Receivables Reported as Sales

Not Applicable.

B. Transfer and Servicing of Financial Assets

Not Applicable.

C. Wash Sales

Not Applicable.

18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans

A. ASO Plans

Not Applicable.

B. ASC Plans

Not Applicable.

- C. Medicare or Other Similarly Structured Cost Based Reimbursement Contract
 - (1) The Company records no revenue explicitly attributable to the cost share and reinsurance components of its Medicare or other similarly structured cost based reimbursement contracts.
 - (2) As of December 31, 2017, the Company has recorded a receivable from CMS of \$61,328 related to the cost share and reinsurance components of administered Medicare products. The Company does not have any additional receivables greater than 10% of the Company's accounts receivable from uninsured accident and health plans or \$10,000
 - (3) As no revenue is recorded in connection with the cost share and reinsurance components of the Company's Medicare or other similarly structured cost based reimbursement contracts, the Company has recorded no allowances and reserves for adjustment of recorded revenues and receivables.
 - (4) The Company has made no adjustment to revenue resulting from audit of receivables related to revenues recorded in the prior period.

19. <u>Direct Premium Written/Produced by Managing General Agents/Third Party Administrators</u>

Not Applicable.

20. Fair Value Measurements

A. (1) The fair value of financial assets at December 31, 2017 were as follows:

	Le	vel 1		Level 2	Level 3	Total
a. Assets at fair value						
Bonds						
U.S. governments	\$		-	\$ -	\$ -	\$ -
Tax-exempt municipal			-	-	-	-
Residential mortgage-backed			-	-	-	-
Corporate debt securities			-	196,000	-	196,000
Total bonds			-	196,000	-	196,000
Total assets at fair value	\$		-	\$ 196,000	\$ -	\$ 196,000
b. Liabilities at fair value	\$		-	\$ -	\$ -	\$
Total liabilities at fair value	\$		-	\$ -	\$ -	\$ -

The Company reports transfers between Level 1 and Level 2 of the fair value hierarchy levels at the end of the reporting period. There were no transfers between Level 1 and Level 2 of the fair value hierarchy between December 31, 2016 and December 31, 2017.

(2) Fair Value Measurements in (Level 3) of the Fair Value Hierarchy

Not Applicable.

(3) The Company reports transfers into or out of Level 3 of the fair value hierarchy levels at the end of the reporting period. There were no transfers into or out of Level 3 of the fair value hierarchy levels between December 31, 2016 and December 31, 2017.

NOTES TO THE FINANCIAL STATEMENTS

- (4) Fair value of actively traded debt securities are based on quoted market prices. Fair value of other debt securities are based on quoted market prices of identical or similar securities or based on observable inputs like interest rates generally using a market valuation approach, or, less frequently, an income valuation approach and are generally classified as Level 2. The Company generally obtains one quoted price for each security from a third party pricing service. These prices are generally derived from recently reported trades for identical or similar securities, including adjustments through the reporting date based upon observable market information. When quoted prices are not available, the third party pricing service may use quoted market prices of comparable securities or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include benchmark yields, reported trades, credit spreads, broker quotes, default rates and prepayment speeds. The Company is responsible for the determination of fair value and as such, the Company performs analysis on the prices received from the third party pricing service to determine whether the prices are reasonable estimates of fair value. The Company's analysis includes a review of monthly price fluctuations as well as a quarterly comparison of the prices received from the pricing service to prices reported by the Company's third party investment advisor. Based on the Company's internal price verification procedures and review of fair value methodology documentation provided by the third party pricing service, there were no material adjustments to the prices obtained from the third party pricing service during the year ended December 31, 2017.
- (5) Derivative Fair Values

Not Applicable.

B. Other Fair Value Disclosures

Not Applicable.

C. Fair Values for All Financial Instruments by Levels 1, 2 and 3

Type of Financial	Αg	gregate Fair									Not I	Practicable
Instrument	Value		Admitted Assets		Level 1		Level 2		Level 3		(Carrying Value)	
Bonds, short-term												
investments and												
cash equivalents	\$	33,728,363	\$	33,867,566	\$	12,536,085	\$	21,192,278	\$	-	\$	-
Total	\$	33,728,363	\$	33,867,566	\$	12,536,085	\$	21,192,278	\$	-	\$	-

D. Financial Instruments for which Not Practicable to Estimate Fair Values

Not Applicable.

21. Other Items

A. Extraordinary Items

Not Applicable.

B. Troubled Debt Restructuring: Debtors

Not Applicable.

C. Other Disclosures and Unusual Items

Not Applicable.

D. Business Interruption Insurance Recoveries

Not Applicable.

E. State Transferable and Non-transferable Tax Credits

Not Applicable.

- F. Subprime Mortgage Related Risk Exposure
 - (1) The Company consults with its external investment managers to assess its subprime mortgage related risk exposure. Certain characteristics are utilized to determine if a mortgage-backed security has subprime exposure. The main characteristics reviewed when determining this are the collateral and structure of the security, the loan purpose, loan documentation, occupancy, geographical location, loan size and type. Subprime mortgage borrowers typically have lower credit scores, lower loan balances and higher loan-to-values than other conforming loans. Management's practices include reviewing quantitative and qualitative credit models that analyze loan-level collateral composition, historical underwriter performance trends, the impact of macroeconomic factors, and issuer risks; as well as reviewing the estimation of security cash flows and monthly model calibrations.
 - (2) Direct exposure through investments in sub-prime mortgage loans.

The Company has no direct exposure through investment to sub-prime mortgage loans.

NOTES TO THE FINANCIAL STATEMENTS

- (3) Direct exposure through other investments:
 - Residential mortgage backed securities No substantial exposure noted.
 - b. Commercial mortgage backed securities No substantial exposure noted.
 - c. Collateralized debt obligations No substantial exposure noted.
 - d. Structured securities No substantial exposure noted.
 - e. Equity investment in SCAs No substantial exposure noted.
 - f. Other assets No substantial exposure noted.
 - g. Total No substantial exposure noted.
- (4) Underwriting exposure to sub-prime mortgage risk through Mortgage Guaranty coverage, Financial Guaranty coverage, Directors and Officers liability coverage, or Errors and Omissions liability coverage.

Not Applicable.

Classification of mortgage related securities is primarily based on information from outside data services, including rating agency actions. When considering our exposure, the Company evaluated the percentage of full documentation loans, percent of owner occupied properties, FICO scores, average margin for ARM loans, percent of loans with prepayment penalties, the existence of non-traditional underwriting standards, among other factors.

G. Retained Assets

Not Applicable.

H. Insurance Linked Securities

Not Applicable.

22. Events Subsequent

On January 1, 2018, the Company will be subject to an annual fee under section 9010 of the Federal Affordable Care Act (ACA). This annual fee will be allocated to individual health insurers based on the ratio of the amount of the entity's net premiums written during the preceding calendar year to the amount of health insurance for any U.S. health risk that is written during the preceding calendar year. A health insurance entity's portion of the annual fee becomes payable once the entity provides health insurance for any U.S. health risk for each calendar year beginning on or after January 1 of the year the fee is due. As of December 31, 2017, the Company has written health insurance subject to the ACA assessment, expects to conduct health insurance business in 2018, and estimates their portion of the annual health insurance industry fee to be payable on September 30, 2018 to be \$1,219,435. This amount is reflected in special surplus. This assessment is expected to impact risk based capital (RBC) by 5.00%. Reporting the ACA assessment as of December 31, 2017 would not have triggered an RBC action level. The Company expects to offset the impact of the health insurance industry fee on its results of operations in 2018 through pretax income improvement; however, there can be no assurance that it will be able to do so.

In 2016 the Company was not subject to the annual fee under Section 9010 of the Federal Health Care Reform Law. The Consolidated Appropriations Act, 2016, which was signed into law on December 18, 2015 imposed a moratorium on the 2017 fee applied to all health insurance providers. Based on the moratorium no segregation was recorded within special surplus for the annual health insurance industry fee related to the 2016 data year. The impact of the annual health insurance industry fee on the Company's operations as of December 31, 2017 and 2016 were as follows:

		 Current Year	Prior Year
A.	Did the reporting entity write accident and health insurance premium that is subject to Section 9010 of the federal Affordable Care Act (YES/NO)?	Yes	
B.	ACA fee assessment payable for the upcoming year	\$ 1,219,435	\$ -
C.	ACA fee assessment paid	\$ -	\$ 2,018,406
D.	Premiums written subject to ACA 9010 assessment	\$ 77,446,774	\$ -
E.	Total Adjusted Capital before surplus adjustment (Five-Year Historical Line 14)	\$ 24,332,983	\$ 31,143,777
F.	Total Adjusted Capital after surplus adjustment (Five-Year Historical Line 14 minus 22B above)	\$ 23,113,548	\$ 31,143,777
G.	Authorized Control Level (Five-Year Historical Line 15)	\$ 2,889,446	\$ 4,358,400
H.	Would reporting the ACA assessment as of December 31, 2017, have triggered an RBC action level (YES/NO)	No	

The Company is not aware of any events or transactions occurring subsequent to the close of the books for this statement which may have a material effect on its financial condition. Subsequent events have been considered through February 23, 2018 for the Statutory Statement issued on February 23, 2018.

NOTES TO THE FINANCIAL STATEMENTS

23. Reinsurance

A. Ceded Reinsurance Report

Section 1 – General Interrogatories

(1) Are any of the reinsurers, listed in Schedule S as non-affiliated, owned in excess of 10.0 percent or controlled, either directly or indirectly, by the company or by any representative, officer, trustee, or director of the company?

Yes() No(X)

(2) Have any policies issued by the company been reinsured with a company chartered in a country other than the United States (excluding U.S. Branches of such companies) that is owned in excess of 10.0 percent or controlled directly or indirectly by an insured, a beneficiary, a creditor or an insured or any other person not primarily engaged in the insurance business?

Yes() No(X)

Section 2 - Ceded Reinsurance Report - Part A

(1) Does the company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than for nonpayment of premium or other similar credits?

Yes() No(X)

(2) Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies?

Yes () No (X)

Section 3 - Ceded Reinsurance Report - Part B

- (1) What is the estimated amount of the aggregate reduction in surplus, (for agreements other than those under which the reinsurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of ALL reinsurance agreements, by either party, as of the date of this statement? Where necessary, the company may consider the current or anticipated experience of the business reinsured in making this estimate. \$0
- (2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the company as of the effective date of the agreement?

Yes () No (X)

B. Uncollectible Reinsurance

Not Applicable.

C. Commutation of Ceded Reinsurance

Not Applicable.

D. Certified Reinsurer Rating Downgraded or Status Subject to Revocation

Not Applicable.

24. Retrospectively Rated Contracts and Contracts Subject to Redetermination

A. The Company estimates accrued retrospective premium adjustments for its Medicare business through a mathematical approach using an algorithm based upon settlement procedures defined by contracts with CMS.

The Company estimates accrued retrospective premium adjustments for its Commercial business based on experience to date, knowledge of the marketplace, and the terms of the risk corridors program with HHS.

- B. The Company records accrued retrospective premium as an adjustment to earned premiums.
- C. The amount of net premiums written by the Company at December 31, 2017 that are subject to retrospective rating features was \$77,258,310, or 100.00% of the total net premiums written. No other net premiums written by the Company are subject to retrospective rating features.
- D. Medical loss ratio rebates required pursuant to the Public Health Service Act

Not Applicable.

NOTES TO THE FINANCIAL STATEMENTS

- E. Risk Sharing Provisions of the Affordable Care Act
 - (1) Did the reporting entity write accident and health insurance premium that is subject to the Affordable Care Act risk-sharing provisions (YES/NO) Yes (X) No ()
 - (2) Impact of Risk Sharing Provisions of the Affordable Care Act on Admitted Assets, Liabilities, and Revenue for the Current Year

a.	Permane Assets	nt ACA Risk Adjustment Program		
	Assets	Premium adjustments receivable due to ACA Risk Adjustment	\$	87,849
	Liabilitie		Ψ	07,0.5
	2.	Risk adjustment user fees payable for ACA Risk Adjustment	\$	9,437
	3.	Premium adjustments payable due to ACA Risk Adjustment	\$	-
	Operatio	ns (Revenue & Expenses)		
	4.	Reported as revenue in premium for accident and health contracts		
	_	(written/collected) due to ACA Risk Adjustment	\$	(3,827,685)
	5.	Reported in expenses as ACA risk adjustment user fees (incurred/paid)	\$	9,794
b.		onal ACA Reinsurance Program		
	Assets	Annual of the second of the se	d.	524 (12
	1. 2.	Amounts recoverable for claims paid due to ACA Reinsurance Amounts recoverable for claims unpaid due to ACA Reinsurance (Contra	\$	534,613
	۷.	Liability)	\$	_
	3.	Amounts receivable relating to uninsured plans for contributions for	Ψ	
	-	ACA Reinsurance	\$	_
	Liabilitie	es		
	4.	Liabilities for contributions payable due to ACA Reinsurance - not		
		reported as ceded premium	\$	-
	5.	Ceded reinsurance premiums payable due to ACA Reinsurance	\$	-
	6.	Liabilities for amounts held under uninsured plans contributions for ACA		
		Reinsurance	\$	-
		ns (Revenues & Expenses)	Φ.	
	7.	Ceded reinsurance premiums due to ACA Reinsurance	\$	-
	8.	Reinsurance recoveries (income statement) due to ACA Reinsurance payments or expected payments	\$	811,274
	9.	ACA Reinsurance contributions – not reported as ceded premiums	\$	011,274
c.		ry ACA Risk Corridors Program	Φ	_
٥.	Assets	ny Men Mask Conndots i Togram		
	1.	Accrued retrospective premium due to ACA Risk Corridors	\$	_
	Liabilities			
	2.	Reserve for rate credits or policy experience rating refunds due to ACA		
		Risk Corridors	\$	-
	Operation	s (Revenues & Expenses)		
	3.	Effect of ACA Risk Corridors on net premium income	\$	80,487
	4.	Effect of ACA Risk Corridors on change in reserves for rate credits	\$	-

NOTES TO THE FINANCIAL STATEMENTS

(3) Roll-forward of Prior Year ACA Risk-sharing Provisions for the Following Asset (Gross of Any Nonadmission) and Liability Balances, Along with the Reasons for Adjustments to Prior Year Balance.

										Unsettled Ba	lances as of
					Diffe	rences	Ad	justments		the Report	
					Prior Year	Prior Year				Cumulative	Cumulative
		ring the Prior iness Written		Paid as of the or on Business	Accrued Less	Accrued Less	To Prior	To Prior		Balance from Prior	Balance from Prior
		nber 31 of the		ore December	Payments	Payments	Year	Year		Years (Col	Years (Col
	Prior	Year	31 of the	Prior Year	(Col 1-3)	(Col 2-4)	Balances	Balances		1-3+7)	2-4+8)
	1	2	3	4	5	6	7	8		9	10
	Receivable	(Payable)	Receivabl e	(Payable)	Receivabl e	(Payable)	Receivable	(Payable)	Ref	Receivable	(Payable)
a. Permanent ACA Risk			C		C	1		l			
Adjustment Program											
1. Premium											
adjustments receivable	_		_		_		_			_	
2. Premium											
adjustments								(2 0.1 - - 2 1)			
(payables) 3. Subtotal ACA		(15,561,527)		(19,477,061)		3,915,534		(3,915,534)	A.		-
Permanent Risk											
Adjustment											
Program b. Transitional ACA	-	(15,561,527)	-	(19,477,061)	-	3,915,534	-	(3,915,534)		-	-
b. Transitional ACA Reinsurance											
Program											
1. Amounts											
recoverable for claims paid	2,792,615		3,315,926		(523,311)		1,057,924		В.	534,613	
2. Amounts	2,792,013		3,313,920		(323,311)		1,037,924		В.	334,013	
recoverable for											
claims unpaid	246,649				246,649		(246,640)		C.		
(contra liability) 3. Amounts	240,049		-		240,049		(246,649)		C.	-	
receivable relating											
to uninsured plans	-		-		-		-			-	
 Liabilities for contributions 											
payable due to											
ACA											
Reinsurance- not											
reported as ceded premium		(161,820)		(161,820)		_		_			_
5. Ceded reinsurance		(101,020)		(101,020)							
premiums payable		(647,282)		(647,282)		-		-			-
Liability for amounts held											
under uninsured											
plans		-		-		-		-			-
7. Subtotal ACA Transitional											
Reinsurance											
Program	3,039,264	(809,102)	3,315,926	(809,102)	(276,662)	-	811,275	-		534,613	-
c. Temporary ACA											
Risk Corridors Program											
 Accrued 											
retrospective											
premium 2. Reserve for rate	-		80,487		(80,487)		80,487		D.	-	
credits or policy											
experience rating											
refunds		-		-		-		-			-
 Subtotal ACA Risk Corridors 											
Program	-	-	80,487	-	(80,487)	_	80,487	-		-	-
d. Total for ACA Risk							-			_	
Sharing Provisions	3,039,264	(16,370,629)	3,396,413	(20,286,163)	(357,149)	3,915,534	891,762	(3,915,534)		534,613	-

Explanations of adjustments

- $A. \ \ Adjustments \ made \ to \ the \ 2016 \ accrual \ for \ finalized \ CMS \ payments \ in \ 2017 \ and \ for \ insurer \ defaults.$
- B. Adjustments recorded to update the 2016 accrual to align with the CMS payment report.
- C. Adjustment recorded as the IBNR for 2016 ran out through March 31, 2017 as the end of the reinsurance submission was occurring.
- D. Adjustments recorded for payments received in 2017.

NOTES TO THE FINANCIAL STATEMENTS

(4) Roll-Forward of Risk Corridors Asset and Liability Balances by Program Benefit Year

											alances as of
	Accrued	During the			Differ		Adj	ustments		the Repor	ting Date
		rior			Prior Year	Prior Year				Cumulative	Cumulative
		Business	Received or P		Accrued	Accrued				Balance	Balance
		ritten	Current Year		Less	Less	To Prior	To Prior		from	from
		ec 31 of the	Written Bef		Payments	Payments	Year	Year		Prior Years	Prior Years
	Prior	Year	of the Pri		(Col 1 -3)	(Col 2 -4)	Balances	Balances		(Col 1-3+7)	(Col 2-4+8)
	1	2	3	4	5	6	7	8		9	10
Risk Corridors Program	Receiva										
Year	ble	(Payable)	Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable)	Ref	Receivable	(Payable)
a. 2014											
1. Accrued											
retrospective premium	-		80,487		(80,487)		80,487		A.	-	
Reserve for rate											
credits or policy											
experience rating											
refunds		-		-		-		-			-
b. 2015											
1. Accrued											
retrospective premium	-		-		-		-			-	
Reserve for rate											
credits or policy											
experience rating											
refunds		-		-		-		-			-
c. 2016											
1. Accrued											
retrospective premium	-		-		-		-			-	
Reserve for rate											
credits or policy											
experience rating											
refunds		-		-		-		-			-
d. Total for Risk					•					<u> </u>	
Corridors	-	-	80,487	-	(80,487)	-	80,487	-		-	

Explanations of adjustments

A. Adjustments recorded for payments received in 2017.

(5) ACA Risk Corridors Receivable as of Reporting Date

		1		2		3		4		5		6
Risk Corridors Program Year	to Fi	nated Amount be Filed or nal Amount ed with CMS	Ir	Non-Accrued Amounts for npairment or ther Reasons	An	nounts received from CMS	-	Assets Balance Gross of Non- admissions) (1-2-3)		Non-admitted Amount	N	et Admitted Asset (4-5)
a. 2014	\$	8,102,093	¢	6,816,190	¢	1,285,903	•		•		¢	
b. 2015	Ф	6,102,093	Э	0,810,190	Ф	1,283,903	Ф	-	Ф	-	Ф	-
c. 2016		7,324,521		7,324,521		-		-		-		-
d. Total												
(a+b+c)	\$	15,426,614	\$	14,140,711	\$	1,285,903	\$	-	\$	-	\$	-

25. Change in Incurred Claims and Claim Adjustment Expenses

Reserves as of December 31, 2016 were \$12,367,542. As of December 31, 2017, \$11,482,124 has been paid for incurred claims and claim adjustment expenses attributable to insured events of prior years. Reserves remaining for prior years are now \$253,210 as a result of re-estimation of unpaid claims and claim adjustment expenses. Therefore, there has been a \$632,208 favorable prior-year development since December 31, 2016. The decrease is generally the result of ongoing analysis of recent loss development trends. Original estimates are increased or decreased as additional information becomes known regarding individual claims. The amounts presented in this footnote exclude any impact related to incurred Medical Incentive Pools and Bonuses, Pharmacy Rebates and other Healthcare Receivable activity. Impact of such receivables can be seen in Footnote 28. The Company did not experience any material prior year claim development on retrospectively rated policies.

26. <u>Intercompany Pooling Arrangements</u>

Not Applicable.

27. Structured Settlements

The Company has no structured settlements.

NOTES TO THE FINANCIAL STATEMENTS

28. Health Care Receivables

A. Pharmaceutical Rebate Receivables

	Estima	te Pharmacy	Ph	armacy Rebates		Actual Rebates	Actual Rebat	tes
	Rebates	s as Reported		as Billed or	Actual Rebates	Received Within 91	Received Mo	ore
	on	Financial		Otherwise	Received Within	to 180 Days of	than 181 Day	,
Quarter	Sta	atements		Confirmed	90 Days of Billing	Billing	after Billing	
12/31/2017	\$	1,073,858	\$	1,073,858	\$ -	\$ -	\$	-
9/30/2017		1,024,335		1,024,335	1,023,925	-		-
6/30/2017		975,675		975,675	974,094	32		-
3/31/2017		966,820		966,820	966,663	-		157
12/31/2016		983,964		983,964	982,416	1,548		-
9/30/2016		783,180		783,180	783,180	-		-
6/30/2016		749,145		749,145	748,529	31		585
3/31/2016		547,968		547,968	547,357	210		401
12/31/2015		326,589		326,589	326,589	4,788		654
9/30/2015		396,510		396,510	396,388	-		122
6/30/2015		404,466		404,466	356,877	38,852	8	,737
3/31/2015		262,472		262,472	262,382	-		90

B. Risk Sharing Receivables

Not Applicable.

29. Participating Policies

The Company has no participating policies.

30. <u>Premium Deficiency Reserves</u>

1. Liability carried for premium deficiency reserves \$ 2,675,000

2. Date of the most recent evaluation of this liability December 31, 2017

3. Was anticipated investment income utilized in the calculation? Yes () No (X)

The Company did recognize the time value of money by discounting future losses at an annual interest rate of 1.29%.

31. Anticipated Salvage and Subrogation

Not Applicable.

GENERAL INTERROGATORIES

PART 1 - COMMON INTERROGATORIES GENERAL

1.1	Is the reporting entity a member of an Insurance Holding Company System c is an insurer?			Yes [X] [No []	
	If yes, complete Schedule Y, Parts 1, 1A and 2						
1.2	If yes, did the reporting entity register and file with its domiciliary State Insura such regulatory official of the state of domicile of the principal insurer in the providing disclosure substantially similar to the standards adopted by the Na its Model Insurance Holding Company System Regulatory Act and model re subject to standards and disclosure requirements substantially similar to the	Holding Company System, a registration statement ational Association of Insurance Commissioners (NAIC) in equilations pertaining thereto, or is the reporting entity	Yes []	X] No []	N/A []
1.3	State Regulating?			Michi	gan		
2.1	Has any change been made during the year of this statement in the charter, I	hy-laws articles of incorporation or deed of settlement of th	ne.				
2.1	reporting entity?			Yes [X] [No []	
2.2	If yes, date of change:			03/01/	2017		
3.1	State as of what date the latest financial examination of the reporting entity w	vas made or is being made.		12/31/	2015		
3.2	State the as of date that the latest financial examination report became available entity. This date should be the date of the examined balance sheet and not			12/31/	<u> 2015</u>		
3.3	State as of what date the latest financial examination report became available domicile or the reporting entity. This is the release date or completion date of examination (balance sheet date).	of the examination report and not the date of the		06/06/	<u> 2017</u>		
3.4	By what department or departments?						
	Michigan Department of Insurance and Financial Services						
3.5	Have all financial statement adjustments within the latest financial examinate statement filed with Departments?	on report been accounted for in a subsequent financial	Yes [] No []	N/A [X]
3.6	Have all of the recommendations within the latest financial examination report	rt been complied with?	Yes [] No []	N/A [X	.]
4.1	4.12 renewals?	of the reporting entity), receive credit or commissions for or ss measured on direct premiums) of: ew business?					
4.2	During the period covered by this statement, did any sales/service organization receive credit or commissions for or control a substantial part (more than 20 premiums) of:	O percent of any major line of business measured on direct					
	4.21 sales of ne	ew business?			-		
5.1	Has the reporting entity been a party to a merger or consolidation during the	period covered by this statement?		Yes [] [No [X]	
5.2	If yes, provide the name of the entity, NAIC Company Code, and state of dor ceased to exist as a result of the merger or consolidation.	micile (use two letter state abbreviation) for any entity that h	as				
	1 Name of Entity	2 3 NAIC Company Code State of Domicile					
6.1	Has the reporting entity had any Certificates of Authority, licenses or registrat revoked by any governmental entity during the reporting period?	tions (including corporate registration, if applicable) suspend		Yes [] [No [X]	
6.2	If yes, give full information:						
7.1	Does any foreign (non-United States) person or entity directly or indirectly con	ntrol 10% or more of the reporting entity?		Yes [] [No [X]	
7.2	If yes,						
	7.21 State the percentage of foreign control;	y is a mutual or reciprocal, the nationality of its manager or	<u>-</u>	0	0.0		_ %
	1 Nationality	2 Type of Entity					

	Is the company a subsidiary of a bank holding company regulated by t If response to 8.1 is yes, please identify the name of the bank holding			Yes [J	No	[X]		
	Is the company affiliated with one or more banks, thrifts or securities fill response to 8.3 is yes, please provide below the names and location regulatory services agency [i.e. the Federal Reserve Board (FRB), the Insurance Corporation (FDIC) and the Securities Exchange Commission of the Securities of the Insurance Corporation (FDIC) and the Securities Exchange Commission of the Insurance Corporation (FDIC) and the Securities Exchange Commission of the Insurance Corporation (FDIC) and the Securities Exchange Commission of the Insurance Corporation (FDIC) and the Securities Exchange Commission of the Insurance Corporation (FDIC) and the Securities Exchange Commission of the Insurance Corporation (FDIC) and the Securities Exchange Commission of the Insurance Corporation (FDIC) and the Securities Exchange Commission of the Insurance Corporation (FDIC) and the Securities Exchange Commission of the Insurance Corporation (FDIC) and the Securities Exchange Commission of the Insurance Corporation (FDIC) and the Securities Exchange Commission of the Insurance Corporation (FDIC) and the Insurance Corporation (FDI	irms? n (city and state of the main office) of any affiliate ne Office of the Comptroller of the Currency (OCC	s regulate), the Fec	d by a fe leral Dep	deral	Yes []	No	[X]
	1 Affiliate Name	2 Location (City, State)	3 FRB	4 OCC	5 FDIC	6 SEC			
).	What is the name and address of the independent certified public according to the independent certified public acc	ountant or accounting firm retained to conduct th	e annual a	udit?		- 	-1		
	PricewaterhouseCoopers LLC, 500 West Main Street, Suite 1800, Lc Has the insurer been granted any exemptions to the prohibited non-au requirements as allowed in Section 7H of the Annual Financial Reportation or regulation?	udit services provided by the certified independer rting Model Regulation (Model Audit Rule), or sul	ostantially	similar s	tate	Yes [1	No	[X]
).2	If the response to 10.1 is yes, provide information related to this exemple.	ption:							
	Has the insurer been granted any exemptions related to the other requirements of the Annual Financial Reporting Model Regulation as allowed for in Section 18A of the Model Regulation, or substantially similar state law or regulation? If the response to 10.3 is yes, provide information related to this exemption:								[X]
).5	Has the reporting entity established an Audit Committee in compliance] No []	l N	/A [
).6	If the response to 10.5 is no or n/a, please explain								
	What is the name, address and affiliation (officer/employee of the reportirm) of the individual providing the statement of actuarial opinion/cert Susan Mateja, Appointed Actuary, 500 West Main Street, Louisville, K	tification?	an actuai	rial consu	ılting				
2.1	Does the reporting entity own any securities of a real estate holding co					Yes []	No	[X]
		estate holding company				_			
		rcels involved							,
2.2	12.13 Total book/adj	ljusted carrying value				5			
3.1	FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTITION What changes have been made during the year in the United States in Not Applicable.	IES ONLY: nanager or the United States trustees of the repo	rting entity	y?					
3.2	Does this statement contain all business transacted for the reporting e	entity through its United States Branch on risks w	herever lo	cated?		Yes []	No	[]
	Have there been any changes made to any of the trust indentures duri					Yes [
l.1	If answer to (13.3) is yes, has the domiciliary or entry state approved the Are the senior officers (principal executive officer, principal financial of similar functions) of the reporting entity subject to a code of ethics, which the thical conduct, including the ethical handling of actual relationships;	fficer, principal accounting officer or controller, or hich includes the following standards?	persons p al and pro	erformin	g] No [Yes [X			
	(b) Full, fair, accurate, timely and understandable disclosure in the per		entity;						
	(c) Compliance with applicable governmental laws, rules and regulatio (d) The prompt internal reporting of violations to an appropriate persor								
	(e) Accountability for adherence to the code.	if of persons identified in the code, and							
	If the response to 14.1 is No, please explain:								
1.2	Has the code of ethics for senior managers been amended?					Yes [X	. 1	No	[]
	If the response to 14.2 is yes, provide information related to amendme					.00 [//	. ,		
	Revised based on general policy and regulatory changes								
	Have any provisions of the code of ethics been waived for any of the s If the response to 14.3 is yes, provide the nature of any waiver(s).	specified officers?				Yes []	No	[X]

	SVO Bank List	entity the beneficiary of a Letter of Credit that is unrelated to ret?				Yes [] No [X]	
15.2	If the response to 15.1 is yes, indicate the American Bankers Association (ABA) Routing Number and the name of the issuing or confirming bank of the Letter of Credit and describe the circumstances in which the Letter of Credit is triggered. 1 American 2 3								
		2		3		4	ļ		
	Association (ABA) Routing Number	Issuing or Confirming Bank Name	Circumstances	That Can Trigger the Letter of Credit		Amo	ount		
								_	
			F DIRECTOR						
16.	thereof?	or sale of all investments of the reporting entity passed upon				Yes [X] No []	
17.	Does the report thereof?	ing entity keep a complete permanent record of the proceedin	gs of its board of dire	ectors and all subordinate committees		Yes [X] No []	
18.		ng entity an established procedure for disclosure to its board of ts officers, directors, trustees or responsible employees that is				Yes [X] No []	
		FIN	ANCIAL						
19.	Has this statem	ent been prepared using a basis of accounting other than Stat inciples)?	utory Accounting Pr	inciples (e.g., Generally Accepted		l seV	1 No [Y	1	
20.1		aned during the year (inclusive of Separate Accounts, exclusiv		20.11 To directors or other officers		\$		0	
				20.12 To stockholders not officers 20.13 Trustees, supreme or grand					
				(Fraternal Only)		\$		(
20.2		loans outstanding at the end of year (inclusive of Separate Ad	ccounts, exclusive of	f 20.21 To directors or other officers					
	policy loans):			20.22 To stockholders not officers					
				20 23 Tructage cuprama or grand					
				(Fraternal Only)		\$			
21.1	Were any asset	s reported in this statement subject to a contractual obligation greported in the statement?	to transfer to another	er party without the liability for such		Vac I	1 No [Y	1	
21.2		amount thereof at December 31 of the current year:		21.21 Rented from others		169 [\$) NO [A]	
	,00, 0.0.0	amount the con at 2000mber of a the same in year.		21.22 Borrowed from others					
				21.23 Leased from others					
				21.24 Other					
22.1	Does this stater guaranty associated	ment include payments for assessments as described in the A ciation assessments?	nnual Statement Ins	tructions other than guaranty fund or					
22.2	If answer is yes	:	22	2.21 Amount paid as losses or risk adj	ustment \$	\$			
				2.22 Amount paid as expenses					
22.1	Doos the report	ing entity report any amounts due from parent, subsidiaries or		2.23 Other amounts paid					
23.1 23.2	If yes, indicate a	any amounts receivable from parent included in the Page 2 am	nount:	or this statement?		\$	3,153	,650	
		INVE	STMENT						
4.01		ocks, bonds and other securities owned December 31 of currencession of the reporting entity on said date? (other than securi				Yes [X] No []	
4.02	. •	nd complete information relating thereto							
4.03	whether collate	ding programs, provide a description of the program including eral is carried on or off-balance sheet. (an alternative is to refe	rence Note 17 where	e this information is also provided)					
4.04		pany's security lending program meet the requirements for a co			Yes [] No [] N/A [Χ	
4.05	If answer to 24.0	04 is yes, report amount of collateral for conforming programs	·			\$		(
4.06	If answer to 24.0	04 is no, report amount of collateral for other programs				\$		(
4.07	Does your secu outset of the o	rities lending program require 102% (domestic securities) and ontract?	105% (foreign secu	urities) from the counterparty at the	Yes [] No [] N/A [Χ	
24.08	Does the report	ing entity non-admit when the collateral received from the cou	nterparty falls below	100%?	Yes [] No [] N/A [Χ	
24.09	Does the report conduct securi	ing entity or the reporting entity 's securities lending agent utili ities lending?	ze the Master Secur	rities lending Agreement (MSLA) to	Yes [] No [] N/A [χ	

24.10	For the reporting entity's security lending program state	e the amount of th	ne following as Decer	nber 31 of the cur	rent year:	
	24.101 Total fair value of reinvested or	ollateral assets re	eported on Schedule	DL. Parts 1 and 2.		\$
	24.102 Total book adjusted/carrying va		•			
	24.103 Total payable for securities len	ding reported on	the liability page		9	\$
25.1	Were any of the stocks, bonds or other assets of the recontrol of the reporting entity, or has the reporting ent force? (Exclude securities subject to Interrogatory 21	ity sold or transfe	rred any assets subj	ect to a put option	contract that is currently in	Yes [X] No []
25.2	If yes, state the amount thereof at December 31 of the	current vear	25.21.9	ubject to repurch:	ase agreements	¢
	in you, state the amount thorour at December of the	ourront your.			repurchase agreements	
			25.23 S	ubject to dollar rep	purchase agreements	\$
			25.24 S	ubject to reverse	dollar repurchase agreements	\$
					n agreements	\$
			25.26 L	etter stock or secu	urities restricted as to sale - Capital Stock	_
			05.07.5	excluding FHLB C	Capital Stock	\$
			25.27 F	HLB Capital Stock	·	\$ 1 002 0/
			25.28 0	n deposit with sta	teser regulatory bodies	\$1,000,04
					al - excluding collateral pledged t	
			25.501	an FHLB		\$
			0= 0 / 0			
					al to FHLB - including assets greements	
			25.32 O	ther		\$
25.3	For category (25.26) provide the following:			2		3
	Nature of Restriction			Description	on	Amount
26.1 26.2	Does the reporting entity have any hedging transaction If yes, has a comprehensive description of the hedging If no, attach a description with this statement.					
27.1	Were any preferred stocks or bonds owned as of Dece issuer, convertible into equity?					Yes [] No [X]
27.2	If yes, state the amount thereof at December 31 of the	current year				\$
28.	Excluding items in Schedule E - Part 3 - Special Depositions, vaults or safety deposit boxes, were all stocks custodial agreement with a qualified bank or trust con Outsourcing of Critical Functions, Custodial or Safeke	s, bonds and othe npany in accorda	r securities, owned the	roughout the curr - General Examir	ent year held pursuant to a nation Considerations, F.	Yes [X] No []
28.01	For agreements that comply with the requirements of the	ne NAIC Financia	l Condition Examiner	s Handbook, com	plete the following:	
	1 Name of Custodian(s)			Custodia	2 n's Address	
	realite of Gastodian(s)	4 Metro Te	ch Center, 16th Floo		NY1-C512, Brooklyn, NY 11245,	Attn: Barbara J.
	JP Morgan Chase					
28.02	For all agreements that do not comply with the requirer and a complete explanation:	ments of the NAIC		Examiners Handb	book, provide the name, location	
	1		2		3	(-)
	Name(s)		Location(s)		Complete Explanati	on(s)
	Have there been any changes, including name change If yes, give full and complete information relating theret		n(s) identified in 28.0	1 during the curre	nt year?	Yes [] No [X]
	1	2		3	_ 4	
	Old Custodian	New Cust	todian	Date of Chan	ge Reasor	1
				<u> </u>		

GENERAL INTERROGATORIES

28.05	Investment management – Identify all investment advisors, investment managers, broker/dealers, including individuals that have the authority to
	make investment decisions on behalf of the reporting entity. For assets that are managed internally by employees of the reporting entity, note as
	such. ["that have access to the investment accounts"; "handle securities"]

	Nan	1 me of Firm or Individual		2 Affiliation						
BLACKROCK FINANCIAL		ENT, INC								
W. Mark Preston				I						
		duals listed in the table for Question 2 () manage more than 10% of the repo						Y	es [X]	No
		unaffiliated with the reporting entity (i. anagement aggregate to more than 5							es [X]	No
For those firms or inc	dividuals l	isted in the table for 28.05 with an aff	iliation code	e of "A" (affiliated	l) or "U" (unaffi	liated), prov	vide the information	n for		
1		2		3	3	1	4			5
0									Inves Manag	ge
Central Registra Depository Nur		Name of Firm or Individua	al le	Legal Entity k	dentifier (LEI)		Registered With		Agree (IMA)	
107105		BLACKROCK FINANCIAL MANAGEMENT, IN		549300LVXYTVJK	(F13M84	The SEC	negistered with		DS	
		,								
If yes, complete the f		c) in the Investment Company Act of	a in Schedu 1940 [Sectio	le D, Part 2 (dive on 5(b)(1)])? 2	ersified accordi	ng to the Se	ecurities and		es []	
	following s	c) in the Investment Company Act of schedule:	1940 [Section Section Section	on 5(b)(1)])?` 2 If Mutual Fund				Boo Car	3 ok/Adjuste rying Valu	d ie
1	following s	c) in the Investment Company Act of	1940 [Section Section Section	on 5(b)(1)])?` 2 If Mutual Fund				Boo Car	3 ok/Adjuste	d ie
1 CUSIP #	ollowing s	c) in the Investment Company Act of schedule:	Name o	2 f Mutual Fund				Boo Car	3 ok/Adjuste rying Valu	d ie
1 CUSIP #	ollowing s	c) in the Investment Company Act of schedule:	Name o	2 f Mutual Fund			3	Boo	3 ok/Adjuste rying Valu	d ie
1 CUSIP #	ollowing s	c) in the Investment Company Act of schedule: the table above, complete the following the table above.	Name o	2 If Mutual Fund ee:	2		3 Amount of M Fund's Book/At Carrying Va	Boc Car	3 ok/Adjuste rying Valu	die
CUSIP # 29.2999 - Total For each mutual fund	ollowing s	c) in the Investment Company Act of schedule: the table above, complete the following the table above.	Name o	2 If Mutual Fund Property of Significations of	2		3 Amount of M Fund's Book/A Carrying Va Attributable t Holding	Boc Car lutual djusted alue to the	3 ok/Adjuste rying Valu	ed ie
1 CUSIP # 29.2999 - Total For each mutual fund	ollowing s	the table above, complete the following	Name o	2 If Mutual Fund Property of Significations of	2 ant Holding of	the	Amount of M Fund's Book/Ar Carrying Va Attributable to Holding	Boc Car	3 ok/Adjuster rying Valu 4	d ie
1 CUSIP # 29.2999 - Total For each mutual fund	ollowing s	the table above, complete the following from above table)	Name o	2 If Mutual Fund Property of Signification Mutual	2 ant Holding of	the	3 Amount of M Fund's Book/Ar Carrying Va Attributable to Holding	Boc Car	3 ok/Adjuster rying Valu 4	ed ie
1 CUSIP # 29.2999 - Total For each mutual functions Name of the following	ollowing s	the table above, complete the following from above table)	Name o	2 If Mutual Fund Property of Signification Mutual	2 ant Holding of	the titute amort	Amount of M Fund's Book/Ac Carrying Va Attributable to Holding	Boc Car lutual djusted alue oo the	3 ok/Adjuster rying Valu 4	ed ie
1 CUSIP # 29.2999 - Total For each mutual functions Name of the following	ollowing s	the table above, complete the following from above table)	Name o	2 on 5(b)(1)])?` 2 of Mutual Fund e: Name of Significa Mutual preferred stocks 1 ment (Admitted)	ant Holding of the state of the	titute amort	Amount of M Fund's Book/At Carrying Va Attributable to Holding ized value or Excess of Statemer ver Fair Value (-), Fair Value over	Boc Car lutual djusted alue oo the	3 ok/Adjuster rying Valu 4	ed ie
1 CUSIP # 29.2999 - Total For each mutual fund Name c	d listed in informatifair value	the table above, complete the following formula of the table above, complete the following formula of the table above table.	Name o	2 on 5(b)(1)])? 2 of Mutual Fund e: Name of Significa Mutual preferred stocks 1 ment (Admitted) Value	ant Holding of the state of the	titute amort	Amount of M Fund's Book/At Carrying Va Attributable to Holding ized value or Excess of Statemen ver Fair Value (-), Fair Value over Statement (+)	lutual djusted alue to the0 .	3 ok/Adjuster rying Valu 4	ed ie
CUSIP # 29.2999 - Total For each mutual function of the second of the following statement value for a second of the second of	d listed in	the table above, complete the following formula of the table above, complete the following formula of the table above table.	Name o	2 on 5(b)(1)])?` 2 of Mutual Fund e: Name of Significa Mutual preferred stocks 1 ment (Admitted) Value33,867,566	ant Holding of the state of the	titute amort	Amount of M Fund's Book/At Carrying Va Attributable to Holding ized value or Excess of Statemen ver Fair Value (-), Fair Value over Statement (+)	lutual djusted alue to the0	3 ok/Adjuster rying Valu 4	ed ie
1 CUSIP # 29.2999 - Total For each mutual fund Name c	d listed in	the table above, complete the following formula of the table above, complete the following formula of the table above table.	Name o	2 on 5(b)(1)])? 2 of Mutual Fund e: Name of Significa Mutual preferred stocks 1 ment (Admitted) Value	ant Holding of the second seco	titute amort	Amount of M Fund's Book/At Carrying Va Attributable to Holding ized value or Excess of Statemen ver Fair Value (-), Fair Value over Statement (+)	lutual djusted alue to the int or	3 ok/Adjuster rying Valu 4	d ie

30.4 Describe the sources or methods utilized in determining the fair values:

Fair value of actively traded debt and equity securities are based on quoted market prices. Fair value of inactively traded debt securities are based on quoted market prices of identical or similar securities or based on observable inputs like interest rates using either a market or income valuation.

31.1 Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D? Yes [] No [X]

31.2 If the answer to 31.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for Yes [] No [] all brokers or custodians used as a pricing source?

31.3 If the answer to 31.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair value for Schedule D:

32.1 Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed? 32.2 If no, list exceptions:

33.	By self-designating 5*Gl securities, the reporting entity is certifying the following elements of each self-designa a. Documentation necessary to permit a full credit analysis of the security does not exist. b. Issuer or obligor is current on all contracted interest and principal payments. c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal.	·		
	Has the reporting entity self-designated 5*GI securities?		Yes [] No [X]
	OTHER			
34.1	Amount of payments to trade associations, service organizations and statistical or rating bureaus, if any?		\$	0
34.2	List the name of the organization and the amount paid if any such payment represented 25% or more of the tot service organizations and statistical or rating bureaus during the period covered by this statement.	tal payments to trade as	sociations,	
	1 Name	2 Amount Paid		
35.1	Amount of payments for legal expenses, if any?		\$	1,750
35.2	List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment during the period covered by this statement.	ents for legal expenses		
	1 Name	2 Amount Paid		
	DEDE PLANAJ	1,750		
36.1	Amount of payments for expenditures in connection with matters before legislative bodies, officers or department	ents of government, if ar	าy?\$	0
36.2	List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment connection with matters before legislative bodies, officers or departments of government during the period co			
	1 Name	2 Amount Paid		
	l			

GENERAL INTERROGATORIES

PART 2 - HEALTH INTERROGATORIES

1.1	Does the reporting entity have any direct Medicare Supplement Insurance in force? If yes, indicate premium earned on U.S. business only.									
1.2										
1.3		What portion of Item (1.2) is not reported on the Medicare Supplement Insurance Experience Exhibit?								
	1.31 Rea	ason for excluding								
4.4	Indicate	amount of payrood aromium attributable to Canadian and/ar Other Alian as	t included in Item (1.0) shows	Φ	0					
1.4 1.5		ndicate amount of earned premium attributable to Canadian and/or Other Alien not included in Item (1.2) above								
1.6	Individua	• • •	Most current three years:	Ф	0					
1.0	individua	policies.	1.61 Total premium earned	¢	0					
			1.62 Total incurred claims	Ψ \$	0					
			1.63 Number of covered lives							
			All years prior to most current three years:							
			1.64 Total premium earned	\$	0					
			1.65 Total incurred claims	.φs	0					
		1.66 Number of covered lives								
1.7	Group po	roup policies: Most current three years:								
			1.71 Total premium earned	\$	0					
			1.72 Total incurred claims	\$	0					
			1.73 Number of covered lives		0					
			All years prior to most current three years:							
			1.74 Total premium earned							
			1.75 Total incurred claims	\$	0					
			1.76 Number of covered lives		0					
_										
2.	Health To	est:	1 2							
			Current Year Prior Year							
	2.1 Pr	emium Numerator	77,258,310128,682,393							
		emium Denominator								
	2.3 Pr	emium Ratio (2.1/2.2)	1.0001.000							
		serve Numerator								
	2.5 Re	serve Denominator	28,075,997							
	2.6 Re	serve Ratio (2.4/2.5)	1.0001.000							
3.1	Has the returned	eporting entity received any endowment or gift from contracting hospitals, when, as and if the earnings of the reporting entity permits?	physicians, dentists, or others that is agreed will be	Yes []	No [X]					
3.2	If yes, giv	e particulars:								
4.1	Have cop depend	ies of all agreements stating the period and nature of hospitals', physiciar ents been filed with the appropriate regulatory agency?	s', and dentists' care offered to subscribers and	Yes [X]	No []					
4.2	If not pre	Yes []	No [X]							
5.1	Does the	Yes [X]	No []							
5.2	If no, exp	lain:								
5.3	Maximun	retained risk (see instructions)	5.31 Comprehensive Medical							
			5.32 Medical Only							
			5.33 Medicare Supplement							
			5.34 Dental & Vision							
			5.35 Other Limited Benefit Plan							
			5.36 Other	\$	0					
6.	Describe hold had agreem	arrangement which the reporting entity may have to protect subscribers a mless provisions, conversion privileges with other carriers, agreements wents:	nd their dependents against the risk of insolvency including ith providers to continue rendering services, and any other							
	Provider compar	contracts include hold harmless and continuation of benefits provisions. Hy.	HMO has an indemnity agreement with the parent							
7.1	Does the	Yes [X]	No []							
7.2	If no, give	e details								
_					00 57:					
8.	Provide t	ne following information regarding participating providers:	8.1 Number of providers at start of reporting year8.2 Number of providers at end of reporting year							
			o.z inumber of providers at end of reporting year.		00,211					
9.1	Does the	reporting entity have business subject to premium rate guarantees?		Yes []	No [X]					
				-	-					
9.2	2 If yes, direct premium earned: 9.21 Business with rate guarantees between 15-36 months\$. 9.22 Business with rate guarantees over 36 months\$.									

10.1	Does the reporting entity have Incentive Pool, Withhold or Bonus Arrangements in its provider contracts?							Yes [X] N	0 []
10.2	If yes: 10.21 Maximum amount payable bonuses						\$ \$	1,103,060	
11.1	Is the reporting entity organized as:				11.13 An Indivi	al Group/Staff Mode dual Practice Asso Model (combination	ciation (IPA), or, .	Yes [] M Yes [] M	No [X]
11.2 11.3 11.4 11.5 11.6	Is the reporting entity subject to Statutory M If yes, show the name of the state requiring If yes, show the amount required		\$	7,725,831					
12.	List service areas in which reporting entity	s license	d to operate:						
	k	Cent, Liv /ashtenaw	ingston, Macomb , Wayne	Name of Service re, Genesee, Gladw , Midland, Monroe	in, Gratiot, Ingh Muskegon, Oakla	nd, St. Clair,			
13.1	Do you act as a custodian for health saving	s accoun	nts?					Yes [] N	ю [Х]
13.2	2 If yes, please provide the amount of custodial funds held as of the reporting date.								0
13.3	3 Do you act as an administrator for health savings accounts?							Yes [] N	o [X]
13.4	If yes, please provide the balance of funds administered as of the reporting date.								0
14.1 14.2	4.1 Are any of the captive affiliates reported on Schedule S, Part 3, authorized reinsurers?								N/A []
	1 2 3 4 Assets Supporting Reserv						Supporting Reserve	e Credit	7
	Company Name		NAIC Company Code	Domiciliary Jurisdiction	Reserve Credit	5 Letters of Credit	Trust Agreements	Other	
15.	Whole Life (Variable Life	er full und whether f	*Ordir derwriting, limited full underwriting, without seconda	nary Life Insurance d underwriting, jet i limited underwritin ry gurarantee)	15.1 [15.2] 15.3 N Includes ssue, "short form	Direct Premium Wri Total Incurred Clain Number of Covered	ince assumed or litten	\$	0
	Universal Life (with or without secondary gurarantee) Variable Universal Life (with or without secondary gurarantee)								

FIVE-YEAR HISTORICAL DATA

		1 2017	2 2016	3 2015	4 2014	5 2013
	Balance Sheet (Pages 2 and 3)	2017	2010	2010	2014	2010
1.	Total admitted assets (Page 2, Line 28)	39 829 632	70 013 161	56 555 955	69,365,545	5 576 193
2.	Total liabilities (Page 3, Line 24)				38,397,943	
3.	Statutory minimum capital and surplus requirement .				5,048,804	
4.	Total capital and surplus (Page 3, Line 33)					
٠.	Income Statement (Page 4)			21,010,010	90,001,002	, 101,701
5.	Total revenues (Line 8)	77 258 310	115 144 569	80 122 394	50 488 035	1 799 432
6.	Total medical and hospital expenses (Line 18)					
7.	Claims adjustment expenses (Line 20)					
8.	Total administrative expenses (Line 21)					
9.	Net underwriting gain (loss) (Line 24)					
10.	Net investment gain (loss) (Line 27)					
11.	Total other income (Lines 28 plus 29)					
12.	Net income or (loss) (Line 32)					
12.	Cash Flow (Page 6)	(2,040,007)	(1,012,420)	1,200,000	(4,200,001)	107,710
13.	Net cash from operations (Line 11)	(16 126 757)	5 255 896	(10.548.950)	20, 338, 668	559,480
10.	Risk-Based Capital Analysis	(10, 120, 707)	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	(10,010,000)	20,000,000	
14.	Total adjusted capital	24 332 983	31 143 777	21 019 513	30 967 602	5 157 754
15.	Authorized control level risk-based capital					
10.	Enrollment (Exhibit 1)	2,000,110	1,000,100			10, 121
16.	Total members at end of period (Column 5, Line 7)	10.610	30.074	17.011	26.255	271
17.	Total members months (Column 6, Line 7)				292,938	
	Operating Percentage (Page 4) (Item divided by Page 4, sum of Lines 2, 3 and 5) x 100.0	,				,
18.	Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0	100.0	100.0	100.0	100.0
19.	Total hospital and medical plus other non-health (Lines 18 plus Line 19)	86.2	85.9	76.4	81.4	70.2
20.	Cost containment expenses		3.8		2.5	
21.	Other claims adjustment expenses					
22.	Total underwriting deductions (Line 23)					
23.	Total underwriting gain (loss) (Line 24)	(3.7)	(10.0)	3.6	(11.2)	14.4
	Unpaid Claims Analysis (U&I Exhibit, Part 2B)					
24.	Total claims incurred for prior years (Line 13, Col. 5)	11,306,070	5,455,644	7,475,729	177,295	0
25.	Estimated liability of unpaid claims-[prior year (Line 13, Col. 6)]	11,290,582	8,858,037	8,076,069	114 , 194	0
	Investments In Parent, Subsidiaries and Affiliates					
26.	Affiliated bonds (Sch. D Summary, Line 12, Col. 1)	0	0	0	0	0
27.	Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)	0	0	0	0	0
28.	Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)	0	0	0	0	0
29.	Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10)	0	0	0	0	0
30.	•					
31.						
33.	Total investment in parent included in Lines 26 to	0	0	0		
30. 31. 32. 33.	Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10)					

SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS

Allocated by States and Territories


		1	1	Allocated by	States and T		inaga Only			
		1	2	3	4	Direct Bus	iness Only 6	7	0	9
			2	3	4	Federal	0	/	8	9
						Employees				
						Health	Life & Annuity			
			Accident &			Benefits	Premiums &	Property/	Total	
		Active	Health	Medicare	Medicaid	Plan	Other	Casualty	Columns 2	Deposit-Type
	States, etc.	Status	Premiums	Title XVIII	Title XIX	Premiums	Considerations	Premiums	Through 7	Contracts
1.	Alabama AL	N	0	0	0	0	0	0	0	0
2.	Alaska AK	N	0	0	0	0	0	0	0	0
3.	Arizona AZ	N	0	0	0	0	0	0	n	0
4.	Arkansas AR	N	Λ	٥	Δ	Δ	0	Δ	0	0
5.			0				 0	0		0
		IN	0		0	0	0	0	0	0
6.	Colorado CO	N	0	0	0	0	0	0	0	0
7.	Connecticut CT	N	0	0	0	0	0	0	0	0
8.	Delaware DE	N	0	0	0	0	0	0	0	0
9.	District of Columbia DC	N	0	0	0	0	0	0	0	0
10.	Florida FL	NN.	0	0	0	0	0	0	0	0
11.	Georgia GA	N	0	0	0	0	0	0	0	0
12.	Hawaii HI	N	0	0	0	0	0	0	0	0
13.	Idaho ID	N	0	0	0	0	0	0	0	0
14.	Illinois	NI	Λ	٥	Λ	o	0	٥	0	0
		N.	0		o	o	0	0 0		0
15.	Indiana IN	N.	0							
16.	lowa IA	N	ļ	ا بِالْ	ļ0	ļ0	ا برا	0	ļ0	}0
17.	Kansas KS	N	0	0	0	0	0	0	ļ0	ļ0
18.	Kentucky KY	N	0	0	0	0	0	0	0	0
19.	Louisiana LA	N	0	0	0	0	0	0	0	0
20.	Maine ME	N	0	0	0	0	0	0	0	0
21.	Maryland MD	N	0	0	0	0	0	0	0	0
	Massachusetts MA	N	0	0	0	Ĺ	0	0	n	0
23.	Michigan MI	ı	18,636,000	58,625,747	n	n	n	0	77.261.747	n
24.	Minnesota MN	NI	0	00,020,141 n	ر د	ر م	ر	0		n
25.		NI	,			u	,		^	^
	Mississippi MS	IV				ļ			ļ	J
26.	Missouri MO	N.			0	0			ļ	} <u>0</u>
27.	Montana MT	N	0	O	ļ0	ļ0	J	0	ļ0	J0
28.	Nebraska NE	N.	ļ0	0	ļ0	ļ0	0	0	ļ0	ļ0
29.	Nevada NV	N	0	0	0	0	0	0	0	0
30.	New Hampshire NH	N	0	0	0	0	0	0	0	0
31.	New Jersey NJ	N	0	0	0	0	0	0	0	0
32.	New Mexico NM	NN	0	0	0	0	0	0	0	0
33.	New York NY	N	0	0	0	0	0	0	0	0
34.	North Carolina NC	N	0	0	0	n	0	0	n	0
35.	North Dakota ND	N N	Ω	0	0	n	0	0	n	0
36.			0			o	0	0		0
	U	NN.	0	0		u		0	0	0
37.	Oklahoma OK	N	0		0		0	0		0
38.	Oregon OR	N	0	0	0	0	0	0	0	0
39.	Pennsylvania PA	N	0	0	0	0	0	0	0	0
40.	Rhode Island RI	N	0	0	0	0	0	0	0	0
41.	South Carolina SC	N	0	0	0	0	0	0	0	0
42.	South Dakota SD	NN	0	0	0	0	0	0	0	0
43.	Tennessee TN	N	0	0	0	0	0	0	0	0
44.	Texas TX	N	0	0	0	0	0	0	0	n
45.	Utah UT	N	0	0	0	0	0	0	0	0
46.	Vermont VT	NN	0	0	0	0	0	0	0	0
		NN.		0		0			0	t
47.	Virginia VA		0		0		0	0		ł
48.	Washington WA	N	0	0	0	0	0	0	0	J0
	West Virginia WV	N	0	0	0	0	0	0	0	ļ0
	Wisconsin WI	N	0	0	0	0	0	0	0	ļ0
51.	Wyoming WY	N	0	0	0	0	0	0	0	0
	American Samoa AS	N	0	0	0	0	0	0	0	0
53.	Guam GU	N	0	0	0	0	0	0	0	0
54.	Puerto Rico PR	N	0	0	0	0	0	0	0	0
	U.S. Virgin Islands VI	N	0	0	0	0	0	0	n	0
56.	Northern Mariana				J					[
55.	Islands MP	N	0	0	0	0	0	0	0	0
57.	Canada CAN	N	0	0	0	0	0	0	0	0
58.	Aggregate other						[[
55.	alien OT	XXX	0	0	0	0	0	0	0	0
59.	Subtotal	XXX	18,636,000	58,625,747	0	0	0	0	77,261,747	0
60.	Reporting entity		10,000,000	00,020,171		u			, 201,171	[
50.	contributions for Employee									
	Benefit Plans	xxx	0	0	0	0	0	0	n	0
61.	Total (Direct Business)	(a) 1	18,636,000	58,625,747	0	0	0	0	77,261,747	0
	DETAILS OF WRITE-INS	(α) Ι	10,000,000	55,525,171	3	3	3	J	,201,171	
58001.		XXX								
58001.							t		t	t
		XXX				 	 		 	
58003.	0	XXX								
58998.	Summary of remaining									
1	write-ins for Line 58 from	VA/4	0	0	0	0	0	0	_	^
E0000	overflow page	XXX	ļ ^U	U	0	ļ0	ا الـــــــــــــــــــــــــــــــــــ	0	ļ0	0
o8999.	Totals (Lines 58001 through									
	58003 plus 58998)(Line 58	vvv	0	0	0	0	0	0	0	0
	above) sed or Chartered - Licensed Ins	XXX		_		_	_			


⁽L) Licensed or Chartered - Licensed Insurance Carrier or Domiciled RRG; (R) Registered - Non-domiciled RRGs; (Q) Qualified - Qualified or Accredited Reinsurer; (E) Eligible - Reporting Entities eligible or approved to write Surplus Lines in the state; (N) None of the above - Not allowed to write business in the state.


Explanation of basis of allocation by states, premiums by state, etc.

The company allocates group premiums to the situs of the contract and individual premiums based on residence.

(a) Insert the number of L responses except for Canada and Other Alien.







OVERFLOW PAGE FOR WRITE-INS

NONE

ALPHABETICAL INDEX

ANNUAL STATEMENT BLANK

Analysis of Operations By Lines of Business	
Assets	
Cash Flow	
Exhibit 1 - Enrollment By Product Type for Health Business Only	
Exhibit 2 - Accident and Health Premiums Due and Unpaid	
Exhibit 3 - Health Care Receivables	
Exhibit 3A - Analysis of Health Care Receivables Collected and Accrued	
Exhibit 4 - Claims Unpaid and Incentive Pool, Withhold and Bonus Exhibit 5 - Amounts Due From Parent, Subsidiaries and Affiliates	
Exhibit 6 - Amounts Due To Parent, Subsidiaries and Affiliates	
Exhibit 7 - Part 1 - Summary of Transactions With Providers	
Exhibit 7 - Part 2 - Summary of Transactions With Intermediaries	
Exhibit 8 - Furniture, Equipment and Supplies Owned	
Exhibit of Capital Gains (Losses)	
Exhibit of Net Investment Income	
Exhibit of Nonadmitted Assets	
Exhibit of Premiums, Enrollment and Utilization (State Page)	
Five-Year Historical Data	
General Interrogatories	
Jurat Page	1
Liabilities, Capital and Surplus	3
Notes To Financial Statements	26
Overflow Page For Write-ins	44
Schedule A - Part 1	E01
Schedule A - Part 2	E02
Schedule A - Part 3	
Schedule A - Verification Between Years	
Schedule B - Part 1	
Schedule B - Part 2	
Schedule B - Part 3	
Schedule B - Verification Between Years	
Schedule BA - Part 1	
Schedule BA - Part 2	
Schedule BA - Part 3	
Schedule BA - Verification Between Years	
Schedule D - Part 1	
Schedule D - Part 1A - Section 1	
Schedule D - Part 1A - Section 2	
Schedule D - Part 2 - Section 1	
Schedule D - Part 2 - Section 2	
Schedule D - Part 3	
Schedule D - Part 5	
Schedule D - Part 6 - Section 1	
Schedule D - Part 6 - Section 2	
Schedule D - Summary By Country	
Schedule D - Verification Between Years	
Schedule DA - Part 1	
Schedule DA - Verification Between Years	
Schedule DB - Part A - Section 1	
Schedule DB - Part A - Section 2	
Schedule DB - Part A - Verification Between Years	
Schedule DB - Part B - Section 1	
Schedule DB - Part B - Section 2	
Schedule DB - Part B - Verification Between Years	SI11
Schedule DB - Part C - Section 1	SI12
Schedule DB - Part C - Section 2	SI13
Schedule DB - Part D - Section 1	E22
Schedule DB - Part D - Section 2	E23
Schedule DB - Verification	SI14
Schedule DL - Part 1	E24
Schedule DL - Part 2	
Schedule E - Part 1 - Cash	
Schedule E - Part 2 - Cash Equivalents	
Schedule E - Part 3 - Special Deposits	
Schedule E - Verification Between Years	SI15

ANNUAL STATEMENT BLANK (Continued)

Schedule S - Part 1 - Section 2	31
Schedule S - Part 2	
Schedule S - Part 3 - Section 2	33
Schedule S - Part 4	34
Schedule S - Part 5	35
Schedule S - Part 6	36
Schedule S - Part 7	
Schedule T - Part 2 - Interstate Compact	
Schedule T - Premiums and Other Considerations	38
Schedule Y - Information Concerning Activities of Insurer Members of a Holding Company Group	40
Schedule Y - Part 1A - Detail of Insurance Holding Company System	41
Schedule Y - Part 2 - Summary of Insurer's Transactions With Any Affiliates	42
Statement of Revenue and Expenses	4
Summary Investment Schedule	SI01
Supplemental Exhibits and Schedules Interrogatories	43
Underwriting and Investment Exhibit - Part 1	
Underwriting and Investment Exhibit - Part 2	9
Underwriting and Investment Exhibit - Part 2A	10
Underwriting and Investment Exhibit - Part 2B	11
Underwriting and Investment Exhibit - Part 2C	12
Underwriting and Investment Exhibit - Part 2D	13
Underwriting and Investment Exhibit - Part 3	14